{
  "id": 113,
  "body": "**Pipeline Disclaimer**\n<br></br>\nThe information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of {date}. Lilly assumes no duty to update this information. \n\nFor competitive reasons, some pipeline molecules are not identified. \n\nProperty of Eli Lilly and Company.",
  "faqs": [
    {
      "id": 770,
      "body": "Lilly defines First Submission as the initial submission of a regulatory dossier to a health authority to obtain regulatory approval for Lilly to market any indication or product form of a potential new medicine in one of the major markets (US, EU, China or Japan).",
      "title": "How does Lilly define First Submission?",
      "page_id": 113,
      "ordering": 8,
      "body_html": "<p>Lilly defines First Submission as the initial submission of a regulatory dossier to a health authority to obtain regulatory approval for Lilly to market any indication or product form of a potential new medicine in one of the major markets (US, EU, China or Japan).</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 780,
      "body": "For competitive reasons, some pipeline molecules are not identified.",
      "title": "Why are some targets undisclosed?",
      "page_id": 113,
      "ordering": 3,
      "body_html": "For competitive reasons, some pipeline molecules are not identified.",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-29T17:23:32.000Z"
    },
    {
      "id": 771,
      "body": "Lilly defines First Registration Dose as the date of the first dose administered in the first large-scale pivotal study designed or intended to support registration in a major market (US, EU, China or Japan). This may occur before all Phase 2 studies have been completed. This dose may be active LY, placebo or comparator.",
      "title": "How does Lilly define First Registration Dose?",
      "page_id": 113,
      "ordering": 7,
      "body_html": "<p>Lilly defines First Registration Dose as the date of the first dose administered in the first large-scale pivotal study designed or intended to support registration in a major market (US, EU, China or Japan). This may occur before all Phase 2 studies have been completed. This dose may be active LY, placebo or comparator.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 784,
      "body": "A new small molecule, or chemical entity, is a molecule that is chemically derived, or synthesized, through chemical processes, and are typically administered orally. A new large molecule, or biologic entity, is comprised of biological products such as proteins, peptides or antibodies, and are typically administered intravenously or subcutaneously.",
      "title": "What is the difference between a small and large molecule?",
      "page_id": 113,
      "ordering": 13,
      "body_html": "<p>A new small molecule, or chemical entity, is a molecule that is chemically derived, or synthesized, through chemical processes, and are typically administered orally. A new large molecule, or biologic entity, is comprised of biological products such as proteins, peptides or antibodies, and are typically administered intravenously or subcutaneously.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 772,
      "body": "<div class=\"row\">\n    <div class=\"columns small-12 medium-6\">\n        <p><strong>α: alpha</strong></p>\n        <p><strong>β: beta</strong></p>\n        <p><strong>NME: new molecular entity</strong></p>\n        <p><strong>NILEX: new indication or line extension</strong></p>\n    </div>\n    <div class=\"columns small-12 medium-6\">\n            <p><span class=\"icon icon-pipeline-check\"></span>&nbsp;&nbsp;regulatory approval achieved</p>\n            <p><span class=\"icon icon-pipeline-bookmark\"></span>&nbsp;&nbsp;milestone achieved</p>\n            <p>\n                <span class=\"icon icon-pipeline-plus\"></span>&nbsp;&nbsp;new to pipeline\n            </p>\n    </div>\n</div>",
      "title": "Abbreviations & Icons",
      "page_id": 113,
      "ordering": 0,
      "body_html": "<div class=\"row\">\n    <div class=\"columns small-12 medium-6\">\n        <p><strong>α: alpha</strong></p>\n        <p><strong>β: beta</strong></p>\n        <p><strong>NME: new molecular entity</strong></p>\n        <p><strong>NILEX: new indication or line extension</strong></p>\n    </div>\n    <div class=\"columns small-12 medium-6\">\n            <p><span class=\"icon icon-pipeline-check\"></span>&nbsp;&nbsp;regulatory approval achieved</p>\n            <p><span class=\"icon icon-pipeline-bookmark\"></span>&nbsp;&nbsp;milestone achieved</p>\n            <p>\n                <span class=\"icon icon-pipeline-plus\"></span>&nbsp;&nbsp;new to pipeline\n            </p>\n    </div>\n</div>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-29T17:25:30.000Z"
    },
    {
      "id": 774,
      "body": "Lilly defines First Efficacy Dose as the date of the first dose administered to patients with the disease the molecule is being studied to treat, in a clinical study in which efficacy is a primary endpoint. The outcome of the clinical study should provide meaningful data on efficacy that drives a decision on whether to pursue development of the targeted indication for the molecule. This dose may be active LY, placebo or comparator.",
      "title": "How does Lilly define First Efficacy Dose?",
      "page_id": 113,
      "ordering": 6,
      "body_html": "<p>Lilly defines First Efficacy Dose as the date of the first dose administered to patients with the disease the molecule is being studied to treat, in a clinical study in which efficacy is a primary endpoint. The outcome of the clinical study should provide meaningful data on efficacy that drives a decision on whether to pursue development of the targeted indication for the molecule. This dose may be active LY, placebo or comparator.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 775,
      "body": "In some cases, the pipeline includes two or more molecules that act on the same disease target. To distinguish these molecules until a nonproprietary name is granted, they are numbered on Lilly’s pipeline website. ",
      "title": "Why are some molecules in the pipeline followed by a 1 or 2?",
      "page_id": 113,
      "ordering": 11,
      "body_html": "<p>In some cases, the pipeline includes two or more molecules that act on the same disease target. To distinguish these molecules until a nonproprietary name is granted, they are numbered on Lilly’s pipeline website. </p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 776,
      "body": "For each molecule, the lead indication, or indication that is furthest along in clinical development, is listed in the molecule’s “box” on the pipeline overview page. If a molecule is being studied for multiple indications, select additional indications will be listed in the molecule’s full description, which is displayed once you click the molecule’s box on the pipeline overview page.\n\nFor New Indication or Line Extension (NILEX) molecules, the indication listed is the new indication undergoing clinical study and not the indication which is already approved for marketing by a regulatory agency.",
      "title": "What is the significance of the indications listed for each molecule?",
      "page_id": 113,
      "ordering": 2,
      "body_html": "<p>For each molecule, the lead indication, or indication that is furthest along in clinical development, is listed in the molecule’s “box” on the pipeline overview page. If a molecule is being studied for multiple indications, select additional indications will be listed in the molecule’s full description, which is displayed once you click the molecule’s box on the pipeline overview page.</p>\n<p>For New Indication or Line Extension (NILEX) molecules, the indication listed is the new indication undergoing clinical study and not the indication which is already approved for marketing by a regulatory agency.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 777,
      "body": "Molecules are listed in alphabetical order by phase in development.",
      "title": "What is the significance of the position of a molecule within a particular phase of development (Phase 1, 2, 3 or Regulatory Review) as compared to other molecules in that same phase?",
      "page_id": 113,
      "ordering": 1,
      "body_html": "<p>Molecules are listed in alphabetical order by phase in development.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 782,
      "body": "Lilly defines First Human Dose as the date of the first dose administered in the initial clinical study of the molecule given to healthy volunteers. This is typically a single-dose pharmacokinetic safety study (study of how the investigational medicine acts on the body over a period of time, from a safety perspective). This dose may be active LY, placebo or comparator. \n\nIn some cases, such as oncology and autoimmunity, the First Human Dose is given to patients with the disease the molecule is being studied to treat.",
      "title": "How does Lilly define First Human Dose?",
      "page_id": 113,
      "ordering": 5,
      "body_html": "<p>Lilly defines First Human Dose as the date of the first dose administered in the initial clinical study of the molecule given to healthy volunteers. This is typically a single-dose pharmacokinetic safety study (study of how the investigational medicine acts on the body over a period of time, from a safety perspective). This dose may be active LY, placebo or comparator. </p>\n<p>In some cases, such as oncology and autoimmunity, the First Human Dose is given to patients with the disease the molecule is being studied to treat.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 773,
      "body": "Some pipeline molecules will be commercialized (sold and marketed) with other companies after the medicine is approved. This is referred to as a commercial collaboration.",
      "title": "What is a commercial collaboration?",
      "page_id": 113,
      "ordering": 12,
      "body_html": "<p>Some pipeline molecules will be commercialized (sold and marketed) with other companies after the medicine is approved. This is referred to as a commercial collaboration.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 781,
      "body": "For molecules in Phase 3 development and under regulatory review, Lilly’s interactive pipeline website includes links to press releases issued January 1, 2010, through the pipeline date listed at the top of the site.\n\nFor announcements related to molecules in other phases (Phase 1, Phase 2, NILEX), as well as broader pipeline announcements, please visit the press release archives in the <a href=\"https://www.lilly.com/newsroom\">Lilly.com Newsroom</a>.",
      "title": "Which molecules include links to press releases and what are the criteria for press release inclusion?",
      "page_id": 113,
      "ordering": 9,
      "body_html": "<p>For molecules in Phase 3 development and under regulatory review, Lilly’s interactive pipeline website includes links to press releases issued January 1, 2010, through the pipeline date listed at the top of the site.</p>\n<p>For announcements related to molecules in other phases (Phase 1, Phase 2, NILEX), as well as broader pipeline announcements, please visit the press release archives in the <a href=\"https://www.lilly.com/newsroom\">Lilly.com Newsroom</a>.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 778,
      "body": "<ul>\n<li>Lilly considers Phase 1 clinical development to be underway once the first human dose has been given.</li>\n\n<li>Lilly considers Phase 2 clinical development to be underway once the first efficacy dose has been given.</li>\n\n<li>Lilly considers Phase 3 clinical development to be underway once the first registration dose has been given.</li>\n\n<li>Lilly considers regulatory review to be underway when the first submission has been made.</li>",
      "title": "How does Lilly determine when a molecule enters a particular phase of clinical development?",
      "page_id": 113,
      "ordering": 4,
      "body_html": "<ul>\n<li>Lilly considers Phase 1 clinical development to be underway once the first human dose has been given.</li>\n\n<li>Lilly considers Phase 2 clinical development to be underway once the first efficacy dose has been given.</li>\n\n<li>Lilly considers Phase 3 clinical development to be underway once the first registration dose has been given.</li>\n\n<li>Lilly considers regulatory review to be underway when the first submission has been made.</li>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 783,
      "body": "Molecules are listed as “milestone achieved” during the quarter after the milestone was achieved. For Q1 2021, milestone achievement occurred April 23, 2021 - July 30, 2021.",
      "title": "When are molecules listed as “milestone achieved”?",
      "page_id": 113,
      "ordering": 14,
      "body_html": "<p>Molecules are listed as “milestone achieved” during the quarter after the milestone was achieved. For Q1 2021, milestone achievement occurred April 23, 2021 - July 30, 2021.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    },
    {
      "id": 779,
      "body": "Lilly defines the start of Phase 2 as the first dose in a clinical study for the purpose of evaluating efficacy, whether that occurs in a Phase 1 cohort or a separate Phase 2 study. Some oncology pipeline molecules are considered by Lilly to be in Phase 2 clinical development, although clinicaltrials.gov lists them as Phase 1 based on a Phase 1 study.",
      "title": "Why are some molecules listed on the pipeline website in Phase 2 clinical development, but noted as Phase 1 on ClinicalTrials.gov?",
      "page_id": 113,
      "ordering": 10,
      "body_html": "<p>Lilly defines the start of Phase 2 as the first dose in a clinical study for the purpose of evaluating efficacy, whether that occurs in a Phase 1 cohort or a separate Phase 2 study. Some oncology pipeline molecules are considered by Lilly to be in Phase 2 clinical development, although clinicaltrials.gov lists them as Phase 1 based on a Phase 1 study.</p>",
      "created_at": "2025-04-28T17:04:01.000Z",
      "updated_at": "2025-04-28T17:04:01.000Z"
    }
  ],
  "info": "Thank you for visiting Lilly’s clinical development pipeline site. This interactive page is designed to give you a better understanding of the molecules and potential indications Lilly is currently developing for people around the world. Below are responses to some frequently asked questions regarding the site’s information and how it is displayed.",
  "intro": "Interested in Lilly clinical trials? Learn more at [LillyTrials.com](https://www.lillytrialguide.com/en-US?utm_source=ldc&utm_medium=organic&utm_campaign=ltg&utm_content=cdp)",
  "title": "Medicines in Development",
  "phases": [
    [],
    [
      {
        "id": 2915,
        "body": "\"FGFR3 Selective\" is a chemical entity being studied for the treatment of cancer.\n",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "FGFR3 Selective",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>&quot;FGFR3 Selective&quot; is a chemical entity being studied for the treatment of cancer.</p>",
        "mainTitle": "FGFR3 Selective",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cancer ",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2916,
        "body": "\"SCAP siRNA \" is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "SCAP siRNA",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>&quot;SCAP siRNA &quot; is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).</p>",
        "mainTitle": "SCAP siRNA",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "MASH",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2918,
        "body": "\"Nisotirostide\" is a biologic entity being studied for the treatment of diabetes.\n",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "Nisotirostide ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>&quot;Nisotirostide&quot; is a biologic entity being studied for the treatment of diabetes.</p>",
        "mainTitle": "Nisotirostide ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Diabetes",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2919,
        "body": "“AT2R Antagonist” is a chemical entity being studied for the treatment of pain.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "AT2R Antagonist",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>“AT2R Antagonist” is a chemical entity being studied for the treatment of pain.</p>",
        "mainTitle": "AT2R Antagonist",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Pain",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 304,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2920,
        "body": "\"SARM1 Inhibitor \" is a chemical entity being studied for the treatment of Neurodegenerative diseases.\n",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "SARM1 Inhibitor",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>&quot;SARM1 Inhibitor &quot; is a chemical entity being studied for the treatment of Neurodegenerative diseases.</p>",
        "mainTitle": "SARM1 Inhibitor",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Neurodegeneration",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2922,
        "body": "“[Ac-225]-PSMA-62” is a radioligand therapy being studied for the treatment of prostate cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "named",
        "title": "[Ac-225]-PSMA-62",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "“[Ac-225]-PSMA-62” is a radioligand therapy being studied for the treatment of prostate cancer.",
        "mainTitle": "[Ac-225]-PSMA-62",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Prostate Cancer ",
        "stateTitle": "NAMED",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:13:52.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2930,
        "body": "\"Glucose sensing insulin receptor agonist\" is a biologic entity being studied for the treatment of diabetes.\n",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "GS Insulin Receptor Agonist",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>&quot;Glucose sensing insulin receptor agonist&quot; is a biologic entity being studied for the treatment of diabetes.</p>",
        "mainTitle": "GS Insulin Receptor Agonist",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Diabetes",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2935,
        "body": "\"Macupatide\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "Macupatide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"Macupatide\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "mainTitle": "Macupatide",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cardiometabolic Health",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2947,
        "body": "PNPLA3 siRNA is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "PNPLA3 siRNA",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "PNPLA3 siRNA is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
        "mainTitle": "PNPLA3 siRNA",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "MASH",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2993,
        "body": "\"FXR Agonist (FXR314)\" is a  biologic entity being studied for the treatment of autoimmune diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "new",
        "title": "FXR Agonist (FXR314)",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"FXR Agonist (FXR314)\" is a  biologic entity being studied for the treatment of autoimmune diseases.",
        "mainTitle": "FXR Agonist (FXR314)",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:28:03.000Z",
        "indication": "Immunology",
        "stateTitle": "NEW",
        "typeFilter": "nme",
        "updated_at": "2025-04-29T15:09:38.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2992,
        "body": "“Anti-VEGF Gene Therapy” is a gene therapy being studied for the treatment of vestibular schwannoma.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "new",
        "title": "Anti-VEGF Gene Therapy    ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "“Anti-VEGF Gene Therapy” is a gene therapy being studied for the treatment of vestibular schwannoma.",
        "mainTitle": "Anti-VEGF Gene Therapy    ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:23:58.000Z",
        "indication": "Vestibular Schwannoma",
        "stateTitle": "NEW",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T19:19:37.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2994,
        "body": "\"Integrin α5β1\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "new",
        "title": "Integrin α5β1",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"Integrin α5β1\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "mainTitle": "Integrin α5β1",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:29:42.000Z",
        "indication": "Cardiometabolic Health",
        "stateTitle": "NEW",
        "typeFilter": "nme",
        "updated_at": "2025-04-29T15:10:07.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2936,
        "body": "\"SNCA siRNA\" is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "SNCA siRNA",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"SNCA siRNA\" is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
        "mainTitle": "SNCA siRNA",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Neurodegeneration",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2944,
        "body": "\"GIP/GLP-1 Coagonist III\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "GIP/GLP-1 Coagonist III ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"GIP/GLP-1 Coagonist III\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "mainTitle": "GIP/GLP-1 Coagonist III ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cardiometabolic Health",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2995,
        "body": "\"PI3Kα Inhibitor (STX-478)\" is a chemical entity being studied for the treatment of cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "new",
        "title": "PI3Kα Inhibitor (STX-478)",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "\"PI3Kα Inhibitor (STX-478)\" is a chemical entity being studied for the treatment of cancer.",
        "mainTitle": "PI3Kα Inhibitor (STX-478)",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:34:59.000Z",
        "indication": "Cancer",
        "stateTitle": "NEW",
        "typeFilter": "nme",
        "updated_at": "2025-04-29T15:10:39.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2937,
        "body": "\"GIPR Agonist Long Acting\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "GIPR Agonist Long Acting  ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"GIPR Agonist Long Acting\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
        "mainTitle": "GIPR Agonist Long Acting  ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cardiometabolic Health",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2948,
        "body": "\"Nectin-4 ADC 1\" is a biologic entity being studied for the treatment of cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "named",
        "title": "Nectin-4 ADC 1",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"Nectin-4 ADC 1\" is a biologic entity being studied for the treatment of cancer.",
        "mainTitle": "Nectin-4 ADC 1",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cancer",
        "stateTitle": "NAMED",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2983,
        "body": "\"FRa ADC\" is a biologic entity being studied for the treatment of cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "FRa ADC ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"FRa ADC\" is a biologic entity being studied for the treatment of cancer.",
        "mainTitle": "FRa ADC ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cancer ",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2951,
        "body": "\"Nectin-4 ADC 2\" is a biologic entity being studied for the treatment of cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "Nectin-4 ADC 2",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "\"Nectin-4 ADC 2\" is a biologic entity being studied for the treatment of cancer.",
        "mainTitle": "Nectin-4 ADC 2",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cancer",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2955,
        "body": "\"Itaconate Mimetic\" is a chemical entity being studied for the treatment of autoimmune diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "Itaconate Mimetic",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>&quot;Itaconate Mimetic&quot; is a chemical entity being studied for the treatment of autoimmune diseases.</p>",
        "mainTitle": "Itaconate Mimetic",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Immunology ",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2964,
        "body": "\"Long-Acting Atrial Natriuretic Peptide\" is a biologic entity being studied for the treatment of Heart Failure.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": null,
        "title": "LA-ANP",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>&quot;Long-Acting Atrial Natriuretic Peptide&quot; is a biologic entity being studied for the treatment of Heart Failure.</p>",
        "mainTitle": "LA-ANP",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Heart Failure",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2966,
        "body": "MAPT siRNA is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "MAPT siRNA",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "MAPT siRNA is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
        "mainTitle": "MAPT siRNA",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Neurodegeneration",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2976,
        "body": "\"SMARCA2 (BRM)\" is a chemical entity being studied for the treatment of cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "SMARCA2 (BRM)",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "\"SMARCA2 (BRM)\" is a chemical entity being studied for the treatment of cancer.",
        "mainTitle": "SMARCA2 (BRM)",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cancer",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2978,
        "body": "\"KRAS G12D\" is a chemical entity being studied for the treatment of cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "KRAS G12D",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "\"KRAS G12D\" is a chemical entity being studied for the treatment of cancer.",
        "mainTitle": "KRAS G12D",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cancer ",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2982,
        "body": "\"Pan KRAS\" is a chemical entity being studied for the treatment of cancer.",
        "news": [],
        "type": "nme",
        "phase": 1,
        "state": "n/a",
        "title": "Pan KRAS",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "\"Pan KRAS\" is a chemical entity being studied for the treatment of cancer.",
        "mainTitle": "Pan KRAS",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Cancer ",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-29T15:08:54.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      }
    ],
    [
      {
        "id": 2917,
        "body": "LY3985863 (Bimagrumab) is a monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding. It is being studied for the treatment of obesity.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Bimagrumab  ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3985863 (Bimagrumab) is a monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding. It is being studied for the treatment of obesity.</p>",
        "mainTitle": "Bimagrumab  ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Obesity",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2921,
        "body": "\"GBA1 Gene Therapy\" is a gene therapy  being developed for patients with Parkinson's disease with GBA1 mutations (PD-GBA).\n",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "GBA1 Gene Therapy   ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>&quot;GBA1 Gene Therapy&quot; is a gene therapy  being developed for patients with Parkinson's disease with GBA1 mutations (PD-GBA).</p>",
        "mainTitle": "GBA1 Gene Therapy   ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Parkinson's Disease",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2925,
        "body": "LY3305677 (Mazdutide) is a mammalian oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist. It is being studied for the treatment of obesity. Note that simultaneous development in China is being conducted by Innovent for T2DM (Ph3) and Obesity (reg review).",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Mazdutide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3305677 (Mazdutide) is a mammalian oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist. It is being studied for the treatment of obesity. Note that simultaneous development in China is being conducted by Innovent for T2DM (Ph3) and Obesity (reg review).",
        "mainTitle": "Mazdutide",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Obesity ",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2926,
        "body": "LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Hidradenitis Suppurativa.\n",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Eltrekibart",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Hidradenitis Suppurativa.</p>",
        "mainTitle": "Eltrekibart",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Hidradenitis Suppurativa ",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2927,
        "body": "LY3561774 (Solbinsiran) is a GalNAc-conjugated mRNA silencing agent that specifically targets ANGPTL3 expression in the liver. The reduction of ANGPTL3 protein will reduce certain classes of circulating lipids. It is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).\n",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Solbinsiran",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3561774 (Solbinsiran) is a GalNAc-conjugated mRNA silencing agent that specifically targets ANGPTL3 expression in the liver. The reduction of ANGPTL3 protein will reduce certain classes of circulating lipids. It is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).</p>",
        "mainTitle": "Solbinsiran",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "CVD",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2924,
        "body": "LY3473329 (Muvalaplin) is a chemical entity that disrupts lipoprotein(a) (Lp[a]) formation. LY3473329 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).\n",
        "news": [
          {
            "id": 2067,
            "url": "https://lilly.mediaroom.com/2024-11-18-Lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-by-up-to-85-at-highest-tested-dose",
            "date": "2024-11-18T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2924,
            "formattedDate": "November 18, 2024",
            "formattedDateTime": "November 18, 2024"
          }
        ],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Muvalaplin",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3473329 (Muvalaplin) is a chemical entity that disrupts lipoprotein(a) (Lp[a]) formation. LY3473329 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).\n",
        "mainTitle": "Muvalaplin",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "ASCVD",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:38:27.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2959,
        "body": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Ulcerative Colitis.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": "n/a",
        "title": "MORF-057 ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Ulcerative Colitis.",
        "mainTitle": "MORF-057 ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Ulcerative Colitis",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2931,
        "body": "\"GBA1 Gene Therapy\" is a gene therapy being developed for patients with Gaucher Disease Type 1, which is an autosomal recessive inherited disease.\n",
        "news": [],
        "type": "indication",
        "phase": 2,
        "state": null,
        "title": "GBA1 Gene Therapy",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>&quot;GBA1 Gene Therapy&quot; is a gene therapy being developed for patients with Gaucher Disease Type 1, which is an autosomal recessive inherited disease.</p>",
        "mainTitle": "GBA1 Gene Therapy",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Gaucher Disease Type 1",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2954,
        "body": "LY3556050 (Mazisotine) is a small molecule SSTR4 agonist designed to modulate somatostatin signaling, impacting nerve excitability, resulting in improved regulation of inflammation and pain. It is being developed for treatment of pain.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Mazisotine",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3556050 (Mazisotine) is a small molecule SSTR4 agonist designed to modulate somatostatin signaling, impacting nerve excitability, resulting in improved regulation of inflammation and pain. It is being developed for treatment of pain.",
        "mainTitle": "Mazisotine",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Pain",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 304,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2996,
        "body": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Rheumatoid Arthritis. ",
        "news": [],
        "type": "indication",
        "phase": 2,
        "state": "new",
        "title": "CD19 Antibody",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Rheumatoid Arthritis. ",
        "mainTitle": "CD19 Antibody",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:39:38.000Z",
        "indication": "Rheumatoid Arthritis",
        "stateTitle": "NEW",
        "typeFilter": "nilex",
        "updated_at": "2025-04-29T15:08:12.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2932,
        "body": "LY3841136 (Eloralintide) is a biologic entity that acts as a selective amylin receptor agonist. It is being studied for the treatment of obesity.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": "named",
        "title": "Eloralintide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3841136 (Eloralintide) is a biologic entity that acts as a selective amylin receptor agonist. It is being studied for the treatment of obesity.",
        "mainTitle": "Eloralintide",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Obesity ",
        "stateTitle": "NAMED",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2941,
        "body": "LY3972406 (Kv1.3 Antagonist) is a highly selective small molecule inhibitor of the ion channel protein Kv1.3. LY3972406 is being studied for the treatment of psoriasis.\n",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Kv1.3 Antagonist",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY3972406 (Kv1.3 Antagonist) is a highly selective small molecule inhibitor of the ion channel protein Kv1.3. LY3972406 is being studied for the treatment of psoriasis.</p>",
        "mainTitle": "Kv1.3 Antagonist",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Psoriasis",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2963,
        "body": "\"GRN Gene Therapy\" is a gene therapy being developed for patients with frontotemporal dementia with GRN mutations (FTD-GRN).\n\n",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "GRN Gene Therapy  ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>&quot;GRN Gene Therapy&quot; is a gene therapy being developed for patients with frontotemporal dementia with GRN mutations (FTD-GRN).</p>",
        "mainTitle": "GRN Gene Therapy  ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Frontotemporal Dementia",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2974,
        "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied to assess initial safety, pharmacokinetic (PK) and efficacy of higher investigational doses in participants with Type 2 Diabetes and Obesity (BMI ≥35).\n",
        "news": [],
        "type": "indication",
        "phase": 2,
        "state": null,
        "title": " Tirzepatide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied to assess initial safety, pharmacokinetic (PK) and efficacy of higher investigational doses in participants with Type 2 Diabetes and Obesity (BMI ≥35).</p>",
        "mainTitle": " Tirzepatide",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Higher Doses",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2958,
        "body": "LY4100511 (Simepdekinra) is a small-molecule inhibitor of the cytokine interleukin (IL)-17 and is being developed as an oral therapy for psoriasis.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": "n/a",
        "title": "Simepdekinra ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY4100511 (Simepdekinra) is a small-molecule inhibitor of the cytokine interleukin (IL)-17 and is being developed as an oral therapy for psoriasis.",
        "mainTitle": "Simepdekinra ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Psoriasis",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:37:25.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2957,
        "body": "LY3848575 (Epiregulin mAb) is a monoclonal antibody that binds to human epiregulin, preventing epiregulin binding to and activation of its receptors. It is being studied for the treatment of chronic pain.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": "n/a",
        "title": "Epiregulin Antibody",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3848575 (Epiregulin mAb) is a monoclonal antibody that binds to human epiregulin, preventing epiregulin binding to and activation of its receptors. It is being studied for the treatment of chronic pain.",
        "mainTitle": "Epiregulin Antibody",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Pain",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 304,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2969,
        "body": "LY3154207 (Mevidalen) is a chemical entity that acts as a positive allosteric modulator of the dopamine receptor D1 and is being studied for the symptomatic treatment of Alzheimer's disease.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Mevidalen",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3154207 (Mevidalen) is a chemical entity that acts as a positive allosteric modulator of the dopamine receptor D1 and is being studied for the symptomatic treatment of Alzheimer's disease.",
        "mainTitle": "Mevidalen",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Symptomatic Alzheimer's disease  ",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2945,
        "body": "LY3857210 (P2X7 Inhibitor) is an oral, highly selective, brain penetrant, small molecule antagonist of the ATP ligand-gated ion channel P2X7, which activates neuronal and non-neuronal cells in the peripheral and central nervous system pain pathways. It is being developed as treatment for chronic pain conditions.\n",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "P2X7 Inhibitor  ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY3857210 (P2X7 Inhibitor) is an oral, highly selective, brain penetrant, small molecule antagonist of the ATP ligand-gated ion channel P2X7, which activates neuronal and non-neuronal cells in the peripheral and central nervous system pain pathways. It is being developed as treatment for chronic pain conditions.</p>",
        "mainTitle": "P2X7 Inhibitor  ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Pain",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 304,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2953,
        "body": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Multiple Sclerosis.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": "named",
        "title": "CD19 Antibody",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Multiple Sclerosis.",
        "mainTitle": "CD19 Antibody",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Multiple Sclerosis",
        "stateTitle": "NAMED",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2960,
        "body": "LY3871801 (Ocadusertib) targets RIPK1, Receptor-interacting serine/threonine-protein kinase 1, a key mediator of cell death and inflammation. LY3871801 is being studied for the treatment of rheumatoid arthritis.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "Ocadusertib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY3871801 (Ocadusertib) targets RIPK1, Receptor-interacting serine/threonine-protein kinase 1, a key mediator of cell death and inflammation. LY3871801 is being studied for the treatment of rheumatoid arthritis.</p>",
        "mainTitle": "Ocadusertib",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Rheumatoid Arthritis",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2970,
        "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
        "news": [
          {
            "id": 2103,
            "url": "https://lilly.mediaroom.com/2024-06-08-Lillys-tirzepatide-was-superior-to-placebo-for-MASH-resolution,-and-more-than-half-of-patients-achieved-improvement-in-fibrosis-at-52-weeks",
            "date": "2024-06-08T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2970,
            "formattedDate": "June 08, 2024",
            "formattedDateTime": "June 08, 2024"
          }
        ],
        "type": "indication",
        "phase": 2,
        "state": null,
        "title": " Tirzepatide   ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).</p>",
        "mainTitle": " Tirzepatide   ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "MASH",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2973,
        "body": "“OTOF Gene Therapy” is a gene therapy being developed for individuals with sensorineural hearing loss due to mutations in the Otoferlin gene. ",
        "news": [
          {
            "id": 2092,
            "url": "https://lilly.mediaroom.com/2024-01-23-Positive-Phase-1-2-Clinical-Trial-Data-for-an-Investigational-Gene-Therapy-for-Genetic-Hearing-Loss-to-be-Presented-at-the-Association-for-Research-in-Otolaryngology-2024-MidWinter-Meeting",
            "date": "2024-01-23T00:00:00.000Z",
            "type": "Press Release",
            "title": "Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2973,
            "formattedDate": "January 23, 2024",
            "formattedDateTime": "January 23, 2024"
          }
        ],
        "type": "nme",
        "phase": 2,
        "state": null,
        "title": "OTOF Gene Therapy",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>“OTOF Gene Therapy” is a gene therapy being developed for individuals with sensorineural hearing loss due to mutations in the Otoferlin gene. </p>",
        "mainTitle": "OTOF Gene Therapy",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Hearing Loss",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2984,
        "body": "LY3549492 (GLP-1 Receptor Non-peptide Agonist II) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.",
        "news": [],
        "type": "nme",
        "phase": 2,
        "state": "n/a",
        "title": "GLP-1R NPA II ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3549492 (GLP-1 Receptor Non-peptide Agonist II) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.",
        "mainTitle": "GLP-1R NPA II ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Obesity ",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-29T15:07:19.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2988,
        "body": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Crohn’s Disease.",
        "news": [],
        "type": "indication",
        "phase": 2,
        "state": "n/a",
        "title": "MORF-057 ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Crohn’s Disease.",
        "mainTitle": "MORF-057 ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Crohn’s Disease",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2989,
        "body": "LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Ulcerative Colitis alone and in combination with mirikizumab.",
        "news": [],
        "type": "indication",
        "phase": 2,
        "state": "n/a",
        "title": "Eltrekibart ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Ulcerative Colitis alone and in combination with mirikizumab.",
        "mainTitle": "Eltrekibart ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Ulcerative Colitis ",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-29T15:06:35.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      }
    ],
    [
      {
        "id": 2923,
        "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied in combination with Venetoclax and Rituximab for the treatment of  R/R CLL.",
        "news": [
          {
            "id": 2068,
            "url": "https://lilly.mediaroom.com/2023-12-11-Updated-Data-from-the-BRUIN-Phase-1-2-Study-of-Pirtobrutinib-in-Chronic-Lymphocytic-Leukemia-and-Mantle-Cell-Lymphoma-Presented-at-the-2023-ASH-Annual-Meeting",
            "date": "2023-12-11T00:00:00.000Z",
            "type": "Press Release",
            "title": "Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2923,
            "formattedDate": "December 11, 2023",
            "formattedDateTime": "December 11, 2023"
          }
        ],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Pirtobrutinib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>&quot;Pirtobrutinib&quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied in combination with Venetoclax and Rituximab for the treatment of  R/R CLL.</p>",
        "mainTitle": "Pirtobrutinib",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "R/R CLL combination",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2928,
        "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of Morbidity and Mortality in Obesity.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": " Tirzepatide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of Morbidity and Mortality in Obesity.</p>",
        "mainTitle": " Tirzepatide",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Morbidity and Mortality in Obesity",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2929,
        "body": "LY3372993 (Remternetug) is a biologic entity that binds to deposited amyloid plaque in the brain and is being studied for the treatment of early Alzheimer's disease, with potential for subcutaneous delivery.\n",
        "news": [],
        "type": "nme",
        "phase": 3,
        "state": null,
        "title": "Remternetug",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3372993 (Remternetug) is a biologic entity that binds to deposited amyloid plaque in the brain and is being studied for the treatment of early Alzheimer's disease, with potential for subcutaneous delivery.</p>",
        "mainTitle": "Remternetug",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Alzheimer's Disease ",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2940,
        "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a first line treatment of CLL.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Pirtobrutinib   ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>&quot;Pirtobrutinib&quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a first line treatment of CLL.</p>",
        "mainTitle": "Pirtobrutinib   ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "1L CLL monotherapy ",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2946,
        "body": "LY3527723 \"Selpercatinib\" is a chemical entity that inhibits the rearranged during transfection (RET) kinase. It is being studied in the treatment of adjuvant RET fusion+ non small cell lung cancer after surgery / chemotherapy / radiotherapy.\n",
        "news": [
          {
            "id": 2085,
            "url": "https://lilly.mediaroom.com/2023-10-21-Lillys-Retevmo-R-selpercatinib-Phase-3-Results-in-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-and-RET-Mutant-Medullary-Thyroid-Cancer-Both-Published-in-The-New-England-Journal-of-Medicine-and-Presented-in-a-Presidential-Symposium-at-ESMO-Con",
            "date": "2023-10-21T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published ",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2946,
            "formattedDate": "October 21, 2023",
            "formattedDateTime": "October 21, 2023"
          },
          {
            "id": 2088,
            "url": "http://lilly.mediaroom.com/2022-04-01-Lilly-Presents-Updated-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-NSCLC-at-the-2022-European-Lung-Cancer-Congress",
            "date": "2022-04-01T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2946,
            "formattedDate": "April 01, 2022",
            "formattedDateTime": "April 01, 2022"
          }
        ],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Selpercatinib ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY3527723 &quot;Selpercatinib&quot; is a chemical entity that inhibits the rearranged during transfection (RET) kinase. It is being studied in the treatment of adjuvant RET fusion+ non small cell lung cancer after surgery / chemotherapy / radiotherapy.</p>",
        "mainTitle": "Selpercatinib ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Adjuvant RET+ NSCLC",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2950,
        "body": "LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of HR+ HER2- advanced or metastatic breast cancer in combination with fulvestrant following progression on a CDK4 & 6 inhibitor and endocrine therapy.\n",
        "news": [
          {
            "id": 2091,
            "url": "http://lilly.mediaroom.com/2023-03-03-U-S-FDA-Broadens-Indication-for-Verzenio-R-abemaciclib-in-HR-,-HER2-,-Node-Positive,-High-Risk-Early-Breast-Cancer",
            "date": "2023-03-03T00:00:00.000Z",
            "type": "Press Release",
            "title": "U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2950,
            "formattedDate": "March 03, 2023",
            "formattedDateTime": "March 03, 2023"
          },
          {
            "id": 2090,
            "url": "http://lilly.mediaroom.com/2022-12-06-Lilly-Announces-Updated-Data-from-the-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Presented-at-SABCS-and-Simultaneously-Published-in-The-Lancet-Oncology",
            "date": "2022-12-06T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2950,
            "formattedDate": "December 06, 2022",
            "formattedDateTime": "December 06, 2022"
          },
          {
            "id": 2089,
            "url": "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium",
            "date": "2022-11-21T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2950,
            "formattedDate": "November 21, 2022",
            "formattedDateTime": "November 21, 2022"
          }
        ],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Abemaciclib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of HR+ HER2- advanced or metastatic breast cancer in combination with fulvestrant following progression on a CDK4 &amp; 6 inhibitor and endocrine therapy.</p>",
        "mainTitle": "Abemaciclib",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "MBC Sequencing",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2968,
        "body": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of chronic rhinosinusitis with nasal polyps.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "n/a",
        "title": "Lebrikizumab ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of chronic rhinosinusitis with nasal polyps.",
        "mainTitle": "Lebrikizumab ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "CRSwNP",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2985,
        "body": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (all PD-L1 expressors) in combination with pembrolizumab and platinum-based chemotherapy.",
        "news": [
          {
            "id": 2093,
            "url": "https://lilly.mediaroom.com/2024-06-01-Updated-Data-from-the-Phase-1-2-Study-of-Olomorasib-in-KRAS-G12C-Mutant-Advanced-Solid-Tumors-Presented-at-the-2024-ASCO-R-Annual-Meeting",
            "date": "2024-06-01T00:00:00.000Z",
            "type": "Press Release",
            "title": "Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2985,
            "formattedDate": "June 01, 2024",
            "formattedDateTime": "June 01, 2024"
          }
        ],
        "type": "nme",
        "phase": 3,
        "state": "n/a",
        "title": "Olomorasib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (all PD-L1 expressors) in combination with pembrolizumab and platinum-based chemotherapy.",
        "mainTitle": "Olomorasib",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "KRAS G12C-mutant NSCLC (All PD-L1)",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:42:43.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2975,
        "body": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (PD-L1 high expressors) in combination with pembrolizumab.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "n/a",
        "title": "Olomorasib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (PD-L1 high expressors) in combination with pembrolizumab.",
        "mainTitle": "Olomorasib",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "KRAS G12C-mutant NSCLC (PD-L1 high)",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:51:40.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2943,
        "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied for the treatment of patients with R/R MCL who have received prior BTKi therapies.\n",
        "news": [
          {
            "id": 2077,
            "url": "https://lilly.mediaroom.com/2023-12-11-Updated-Data-from-the-BRUIN-Phase-1-2-Study-of-Pirtobrutinib-in-Chronic-Lymphocytic-Leukemia-and-Mantle-Cell-Lymphoma-Presented-at-the-2023-ASH-Annual-Meeting",
            "date": "2023-12-11T00:00:00.000Z",
            "type": "Press Release",
            "title": "Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2943,
            "formattedDate": "December 11, 2023",
            "formattedDateTime": "December 11, 2023"
          },
          {
            "id": 2069,
            "url": "https://lilly.mediaroom.com/2023-11-02-Lilly-Announces-Details-of-Pirtobrutinib-Presentations-in-B-Cell-Malignancies-at-2023-ASH-Annual-Meeting",
            "date": "2023-11-02T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2943,
            "formattedDate": "November 02, 2023",
            "formattedDateTime": "November 02, 2023"
          },
          {
            "id": 2070,
            "url": "http://lilly.mediaroom.com/2023-01-27-U-S-FDA-Approves-Jaypirca-TM-pirtobrutinib-,-the-First-and-Only-Non-Covalent-Reversible-BTK-Inhibitor,-for-Adult-Patients-with-Relapsed-or-Refractory-Mantle-Cell-Lymphoma-After-at-Least-Two-Lines-of-Systemic-Therapy,-Including-a-BTK-Inhibitor",
            "date": "2023-01-27T00:00:00.000Z",
            "type": "Press Release",
            "title": "U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2943,
            "formattedDate": "January 27, 2023",
            "formattedDateTime": "January 27, 2023"
          }
        ],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Pirtobrutinib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>&quot;Pirtobrutinib&quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied for the treatment of patients with R/R MCL who have received prior BTKi therapies.</p>",
        "mainTitle": "Pirtobrutinib",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "R/R MCL monotherapy",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2965,
        "body": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.\n",
        "news": [
          {
            "id": 2098,
            "url": "http://lilly.mediaroom.com/2023-06-23-Lillys-phase-2-results-published-in-the-New-England-Journal-of-Medicine-show-orforglipron,-a-once-daily-oral-nonpeptide-GLP-1-receptor-agonist,-achieved-up-to-14-7-mean-weight-reduction-at-36-weeks-in-adults-with-obesity-or-overweight",
            "date": "2023-06-23T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweigh",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2965,
            "formattedDate": "June 23, 2023",
            "formattedDateTime": "June 23, 2023"
          }
        ],
        "type": "nme",
        "phase": 3,
        "state": null,
        "title": "Orforglipron ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.</p>",
        "mainTitle": "Orforglipron ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Obesity",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2977,
        "body": "LY3484356 “Imlunestrant\" is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).\n",
        "news": [
          {
            "id": 2101,
            "url": "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium",
            "date": "2022-11-21T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2977,
            "formattedDate": "November 21, 2022",
            "formattedDateTime": "November 21, 2022"
          }
        ],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Imlunestrant  ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY3484356 “Imlunestrant&quot; is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).</p>",
        "mainTitle": "Imlunestrant  ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Adjuvant Breast Cancer",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2949,
        "body": "LY3819469 (Lepodisiran) is a GalNAc-conjugated small interfering RNA (siRNA) that inhibits the production of apolipoprotein(a) (Apo[a]), thereby reducing levels of lipoprotein(a) (Lp[a]). LY3819469 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).",
        "news": [
          {
            "id": 2108,
            "url": "https://lilly.mediaroom.com/2025-03-30-Lillys-lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor,-lipoprotein-a-,-by-nearly-94-from-baseline-at-the-highest-tested-dose-in-adults-with-elevated-levels",
            "date": "2025-03-30T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels",
            "created_at": "2025-04-29T17:27:37.000Z",
            "updated_at": "2025-04-29T17:28:09.000Z",
            "molecule_id": 2949,
            "formattedDate": "March 30, 2025",
            "formattedDateTime": "March 30, 2025"
          }
        ],
        "type": "nme",
        "phase": 3,
        "state": "named",
        "title": "Lepodisiran",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3819469 (Lepodisiran) is a GalNAc-conjugated small interfering RNA (siRNA) that inhibits the production of apolipoprotein(a) (Apo[a]), thereby reducing levels of lipoprotein(a) (Lp[a]). LY3819469 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).",
        "mainTitle": "Lepodisiran",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "ASCVD",
        "stateTitle": "NAMED",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2997,
        "body": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with moderate-to-severe plaque psoriasis and obesity or overweight.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "n/a",
        "title": "Ixekizumab + Tirzepatide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with moderate-to-severe plaque psoriasis and obesity or overweight.",
        "mainTitle": "Ixekizumab + Tirzepatide",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:49:08.000Z",
        "indication": "Psoriasis",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-29T15:11:19.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2999,
        "body": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in Adjuvant KRAS G12C-mutant resected NSCLC in combination with pembrolizumab.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "new",
        "title": "Olomorasib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in Adjuvant KRAS G12C-mutant resected NSCLC in combination with pembrolizumab.",
        "mainTitle": "Olomorasib",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:52:04.000Z",
        "indication": "Adjuvant KRAS G12C-mutant resected NSCLC",
        "stateTitle": "NEW",
        "typeFilter": "nilex",
        "updated_at": "2025-04-29T15:47:17.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2998,
        "body": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with active psoriatic arthritis and obesity or overweight.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "n/a",
        "title": "Ixekizumab + Tirzepatide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with active psoriatic arthritis and obesity or overweight.",
        "mainTitle": "Ixekizumab + Tirzepatide",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:50:23.000Z",
        "indication": " Psoriatic Arthritis",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-29T15:11:08.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2933,
        "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of adverse CV outcomes in patients with type 2 diabetes.\n",
        "news": [
          {
            "id": 2099,
            "url": "http://lilly.mediaroom.com/2021-05-20-Lillys-tirzepatide-achieves-all-primary-and-key-secondary-study-outcomes-against-insulin-glargine-in-adults-with-type-2-diabetes-and-increased-cardiovascular-risk-in-SURPASS-4-trial",
            "date": "2021-05-20T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2933,
            "formattedDate": "May 20, 2021",
            "formattedDateTime": "May 20, 2021"
          },
          {
            "id": 2100,
            "url": "http://lilly.mediaroom.com/index.php?s=9042&item=138059",
            "date": "2020-06-09T00:00:00.000Z",
            "type": "Press Release",
            "title": "First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2933,
            "formattedDate": "June 09, 2020",
            "formattedDateTime": "June 09, 2020"
          }
        ],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": " Tirzepatide  ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of adverse CV outcomes in patients with type 2 diabetes.</p>",
        "mainTitle": " Tirzepatide  ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "CV Outcomes",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2942,
        "body": "LY3209590 \"Insulin Efsitora Alfa\" is a biologic entity comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.\n",
        "news": [
          {
            "id": 2076,
            "url": "https://lilly.mediaroom.com/2024-09-10-Once-weekly-dose-of-insulin-efsitora-alfa-delivers-A1C-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes",
            "date": "2024-09-10T00:00:00.000Z",
            "type": "Press Release",
            "title": "Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2942,
            "formattedDate": "September 10, 2024",
            "formattedDateTime": "September 10, 2024"
          },
          {
            "id": 2072,
            "url": "https://lilly.mediaroom.com/2024-09-05-In-a-first-of-its-kind-fixed-dose-study,-once-weekly-insulin-efsitora-alfa-leads-to-A1C-reduction-similar-to-daily-insulin",
            "date": "2024-09-05T00:00:00.000Z",
            "type": "Press Release",
            "title": "In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2942,
            "formattedDate": "September 05, 2024",
            "formattedDateTime": "September 05, 2024"
          },
          {
            "id": 2074,
            "url": "https://lilly.mediaroom.com/2024-05-16-With-Once-a-Week-Dosing,-Insulin-Efsitora-Alfa-Delivers-A1C-Reduction-and-Safety-Profile-Consistent-with-Daily-Insulin",
            "date": "2024-05-16T00:00:00.000Z",
            "type": "Press Release",
            "title": "With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2942,
            "formattedDate": "May 16, 2024",
            "formattedDateTime": "May 16, 2024"
          }
        ],
        "type": "nme",
        "phase": 3,
        "state": null,
        "title": "Insulin Efsitora Alfa",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3209590 &quot;Insulin Efsitora Alfa&quot; is a biologic entity comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.</p>",
        "mainTitle": "Insulin Efsitora Alfa",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Diabetes",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2990,
        "body": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of Obstructive Sleep Apnea.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "n/a",
        "title": "Orforglipron",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of Obstructive Sleep Apnea.",
        "mainTitle": "Orforglipron",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Obstructive Sleep Apnea",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-29T15:05:59.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2934,
        "body": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of type 2 diabetes.\n",
        "news": [
          {
            "id": 2109,
            "url": "https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically",
            "date": "2025-04-17T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial",
            "created_at": "2025-04-29T17:29:34.000Z",
            "updated_at": "2025-04-29T17:30:03.000Z",
            "molecule_id": 2934,
            "formattedDate": "April 17, 2025",
            "formattedDateTime": "April 17, 2025"
          },
          {
            "id": 2104,
            "url": "http://lilly.mediaroom.com/2023-06-23-Lillys-phase-2-results-published-in-the-New-England-Journal-of-Medicine-show-orforglipron,-a-once-daily-oral-nonpeptide-GLP-1-receptor-agonist,-achieved-up-to-14-7-mean-weight-reduction-at-36-weeks-in-adults-with-obesity-or-overweight",
            "date": "2023-06-23T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweigh",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2934,
            "formattedDate": "June 23, 2023",
            "formattedDateTime": "June 23, 2023"
          }
        ],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Orforglipron ",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "<p>LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of type 2 diabetes.</p>",
        "mainTitle": "Orforglipron ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Diabetes",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2939,
        "body": "LY3002813 (N3pG-Ab MAb) is a biologic entity that binds to deposited amyloid plaque in brain and is being studied for the treatment of preclinical Alzheimer's disease.\n",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": null,
        "title": "Donanemab",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3002813 (N3pG-Ab MAb) is a biologic entity that binds to deposited amyloid plaque in brain and is being studied for the treatment of preclinical Alzheimer's disease.</p>",
        "mainTitle": "Donanemab",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Preclinical Alzheimer's Disease ",
        "stateTitle": "",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 302,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2952,
        "body": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.  It is being studied for the treatment of T2DM.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "named",
        "title": "Retatrutide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.  It is being studied for the treatment of T2DM.",
        "mainTitle": "Retatrutide",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Diabetes",
        "stateTitle": "NAMED",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2956,
        "body": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied for the treatment of Obesity, Osteoarthritis, and Obstructive Sleep Apnea with a planned simultaneous submission strategy.\n",
        "news": [
          {
            "id": 2102,
            "url": "http://lilly.mediaroom.com/2023-06-26-Lillys-phase-2-retatrutide-results-published-in-The-New-England-Journal-of-Medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-and-overweight",
            "date": "2023-06-26T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2956,
            "formattedDate": "June 26, 2023",
            "formattedDateTime": "June 26, 2023"
          }
        ],
        "type": "nme",
        "phase": 3,
        "state": null,
        "title": "Retatrutide ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "<p>LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied for the treatment of Obesity, Osteoarthritis, and Obstructive Sleep Apnea with a planned simultaneous submission strategy.</p>",
        "mainTitle": "Retatrutide ",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Obesity, OA, OSA",
        "stateTitle": "",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": null,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": null
      },
      {
        "id": 2967,
        "body": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied the reduction of adverse CV and renal outcomes in patients with obesity.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "n/a",
        "title": "Retatrutide ",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied the reduction of adverse CV and renal outcomes in patients with obesity.",
        "mainTitle": "Retatrutide ",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "CV / Renal Outcomes",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2972,
        "body": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of allergic rhinitis triggered by perennial allergens.",
        "news": [],
        "type": "indication",
        "phase": 3,
        "state": "n/a",
        "title": "Lebrikizumab",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of allergic rhinitis triggered by perennial allergens.",
        "mainTitle": "Lebrikizumab",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "Allergic Rhinitis (perennial allergens)",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:04:00.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 301,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      }
    ],
    [
      {
        "id": 2938,
        "body": "LY3484356 “Imlunestrant\" is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of 2nd line Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) metastatic Breast Cancer (mBC) as a monotherapy and in combination with abemaciclib.",
        "news": [
          {
            "id": 2075,
            "url": "https://lilly.mediaroom.com/2024-12-11-Lillys-Imlunestrant,-an-Oral-SERD,-Significantly-Improved-Progression-Free-Survival-as-Monotherapy-and-in-Combination-with-Verzenio-R-abemaciclib-in-Patients-with-ER-,-HER2-Advanced-Breast-Cancer",
            "date": "2024-12-11T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2938,
            "formattedDate": "December 11, 2024",
            "formattedDateTime": "December 11, 2024"
          },
          {
            "id": 2073,
            "url": "https://lilly.mediaroom.com/2024-11-01-Lilly-to-Present-Results-from-Phase-3-EMBER-3-Study-of-Imlunestrant,-an-Oral-SERD,-and-Additional-Results-from-Its-Breast-Cancer-Portfolio-at-the-San-Antonio-Breast-Cancer-Symposium",
            "date": "2024-11-01T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2938,
            "formattedDate": "November 01, 2024",
            "formattedDateTime": "November 01, 2024"
          },
          {
            "id": 2071,
            "url": "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium",
            "date": "2022-11-21T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2938,
            "formattedDate": "November 21, 2022",
            "formattedDateTime": "November 21, 2022"
          }
        ],
        "type": "nme",
        "phase": 4,
        "state": "n/a",
        "title": "Imlunestrant",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "LY3484356 “Imlunestrant\" is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of 2nd line Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) metastatic Breast Cancer (mBC) as a monotherapy and in combination with abemaciclib.",
        "mainTitle": "Imlunestrant",
        "typeTitle": "NME",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "ER+ HER2- mBC",
        "stateTitle": "N/A",
        "typeFilter": "nme",
        "updated_at": "2025-04-28T19:29:44.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      },
      {
        "id": 2991,
        "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of chronic heart failure with preserved ejection fraction.",
        "news": [
          {
            "id": 2086,
            "url": "https://lilly.mediaroom.com/2024-11-16-Lillys-tirzepatide-reduced-the-risk-of-worsening-heart-failure-events-by-38-in-adults-with-heart-failure-with-preserved-ejection-fraction-HFpEF-and-obesity",
            "date": "2024-11-16T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2991,
            "formattedDate": "November 16, 2024",
            "formattedDateTime": "November 16, 2024"
          },
          {
            "id": 2084,
            "url": "https://lilly.mediaroom.com/2024-08-01-Lillys-tirzepatide-successful-in-phase-3-study-showing-benefit-in-adults-with-heart-failure-with-preserved-ejection-fraction-and-obesity",
            "date": "2024-08-01T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2991,
            "formattedDate": "August 01, 2024",
            "formattedDateTime": "August 01, 2024"
          }
        ],
        "type": "indication",
        "phase": 4,
        "state": "n/a",
        "title": "Tirzepatide",
        "page_id": 113,
        "modality": "biologic",
        "body_html": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of chronic heart failure with preserved ejection fraction.",
        "mainTitle": "Tirzepatide",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": "HFpEF",
        "stateTitle": "N/A",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T19:30:04.000Z",
        "collaboration": false,
        "modalityTitle": "Large Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 303,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": false
      }
    ],
    [
      {
        "id": 2971,
        "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a monotherapy for the treatment of  R/R CLL in BTK pre-treated patients.",
        "news": [
          {
            "id": 2097,
            "url": "https://lilly.mediaroom.com/2024-12-09-Phase-3-results-for-Lillys-Jaypirca-R-pirtobrutinib-in-covalent-BTK-inhibitor-pre-treated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-to-be-presented-at-the-2024-ASH-Annual-Meeting",
            "date": "2024-12-09T00:00:00.000Z",
            "type": "Press Release",
            "title": "Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2971,
            "formattedDate": "December 09, 2024",
            "formattedDateTime": "December 09, 2024"
          },
          {
            "id": 2095,
            "url": "https://lilly.mediaroom.com/2024-11-05-Lilly-announces-details-of-presentations-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting",
            "date": "2024-11-05T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2971,
            "formattedDate": "November 05, 2024",
            "formattedDateTime": "November 05, 2024"
          },
          {
            "id": 2094,
            "url": "https://lilly.mediaroom.com/2023-12-11-Updated-Data-from-the-BRUIN-Phase-1-2-Study-of-Pirtobrutinib-in-Chronic-Lymphocytic-Leukemia-and-Mantle-Cell-Lymphoma-Presented-at-the-2023-ASH-Annual-Meeting",
            "date": "2023-12-11T00:00:00.000Z",
            "type": "Press Release",
            "title": "Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2971,
            "formattedDate": "December 11, 2023",
            "formattedDateTime": "December 11, 2023"
          },
          {
            "id": 2096,
            "url": "https://lilly.mediaroom.com/2023-11-02-Lilly-Announces-Details-of-Pirtobrutinib-Presentations-in-B-Cell-Malignancies-at-2023-ASH-Annual-Meeting",
            "date": "2023-11-02T00:00:00.000Z",
            "type": "Press Release",
            "title": "Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting",
            "created_at": "2025-04-28T17:04:01.000Z",
            "updated_at": "2025-04-28T17:04:01.000Z",
            "molecule_id": 2971,
            "formattedDate": "November 02, 2023",
            "formattedDateTime": "November 02, 2023"
          }
        ],
        "type": "indication",
        "phase": 5,
        "state": "milestone",
        "title": "Pirtobrutinib",
        "page_id": 113,
        "modality": "chemical",
        "body_html": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a monotherapy for the treatment of  R/R CLL in BTK pre-treated patients.",
        "mainTitle": "Pirtobrutinib",
        "typeTitle": "New Indication",
        "created_at": "2025-04-28T17:04:00.000Z",
        "indication": " R/R CLL monotherapy",
        "stateTitle": "MILESTONE",
        "typeFilter": "nilex",
        "updated_at": "2025-04-28T17:53:36.000Z",
        "collaboration": false,
        "modalityTitle": "Small Molecule",
        "pronunciation": null,
        "featured_links": [],
        "clinical_studies": [],
        "therapeutic_area_id": 300,
        "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
        "regulatory_approval_achieved": true
      }
    ]
  ],
  "approver": "Jennifer Lyn Scroggins",
  "end_date": "May 2, 2025",
  "body_html": "**Pipeline Disclaimer**\n<br></br>\nThe information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of {date}. Lilly assumes no duty to update this information. \n\nFor competitive reasons, some pipeline molecules are not identified. \n\nProperty of Eli Lilly and Company.",
  "info_html": "Thank you for visiting Lilly’s clinical development pipeline site. This interactive page is designed to give you a better understanding of the molecules and potential indications Lilly is currently developing for people around the world. Below are responses to some frequently asked questions regarding the site’s information and how it is displayed.",
  "molecules": [
    {
      "id": 2915,
      "body": "\"FGFR3 Selective\" is a chemical entity being studied for the treatment of cancer.\n",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "FGFR3 Selective",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>&quot;FGFR3 Selective&quot; is a chemical entity being studied for the treatment of cancer.</p>",
      "mainTitle": "FGFR3 Selective",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cancer ",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2916,
      "body": "\"SCAP siRNA \" is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "SCAP siRNA",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>&quot;SCAP siRNA &quot; is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).</p>",
      "mainTitle": "SCAP siRNA",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "MASH",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2917,
      "body": "LY3985863 (Bimagrumab) is a monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding. It is being studied for the treatment of obesity.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Bimagrumab  ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3985863 (Bimagrumab) is a monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding. It is being studied for the treatment of obesity.</p>",
      "mainTitle": "Bimagrumab  ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Obesity",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2918,
      "body": "\"Nisotirostide\" is a biologic entity being studied for the treatment of diabetes.\n",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "Nisotirostide ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>&quot;Nisotirostide&quot; is a biologic entity being studied for the treatment of diabetes.</p>",
      "mainTitle": "Nisotirostide ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Diabetes",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2919,
      "body": "“AT2R Antagonist” is a chemical entity being studied for the treatment of pain.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "AT2R Antagonist",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>“AT2R Antagonist” is a chemical entity being studied for the treatment of pain.</p>",
      "mainTitle": "AT2R Antagonist",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Pain",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 304,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2921,
      "body": "\"GBA1 Gene Therapy\" is a gene therapy  being developed for patients with Parkinson's disease with GBA1 mutations (PD-GBA).\n",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "GBA1 Gene Therapy   ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>&quot;GBA1 Gene Therapy&quot; is a gene therapy  being developed for patients with Parkinson's disease with GBA1 mutations (PD-GBA).</p>",
      "mainTitle": "GBA1 Gene Therapy   ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Parkinson's Disease",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2920,
      "body": "\"SARM1 Inhibitor \" is a chemical entity being studied for the treatment of Neurodegenerative diseases.\n",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "SARM1 Inhibitor",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>&quot;SARM1 Inhibitor &quot; is a chemical entity being studied for the treatment of Neurodegenerative diseases.</p>",
      "mainTitle": "SARM1 Inhibitor",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Neurodegeneration",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2923,
      "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied in combination with Venetoclax and Rituximab for the treatment of  R/R CLL.",
      "news": [
        {
          "id": 2068,
          "url": "https://lilly.mediaroom.com/2023-12-11-Updated-Data-from-the-BRUIN-Phase-1-2-Study-of-Pirtobrutinib-in-Chronic-Lymphocytic-Leukemia-and-Mantle-Cell-Lymphoma-Presented-at-the-2023-ASH-Annual-Meeting",
          "date": "2023-12-11T00:00:00.000Z",
          "type": "Press Release",
          "title": "Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2923,
          "formattedDate": "December 11, 2023",
          "formattedDateTime": "December 11, 2023"
        }
      ],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Pirtobrutinib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>&quot;Pirtobrutinib&quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied in combination with Venetoclax and Rituximab for the treatment of  R/R CLL.</p>",
      "mainTitle": "Pirtobrutinib",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "R/R CLL combination",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2925,
      "body": "LY3305677 (Mazdutide) is a mammalian oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist. It is being studied for the treatment of obesity. Note that simultaneous development in China is being conducted by Innovent for T2DM (Ph3) and Obesity (reg review).",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Mazdutide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3305677 (Mazdutide) is a mammalian oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist. It is being studied for the treatment of obesity. Note that simultaneous development in China is being conducted by Innovent for T2DM (Ph3) and Obesity (reg review).",
      "mainTitle": "Mazdutide",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Obesity ",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2926,
      "body": "LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Hidradenitis Suppurativa.\n",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Eltrekibart",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Hidradenitis Suppurativa.</p>",
      "mainTitle": "Eltrekibart",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Hidradenitis Suppurativa ",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2927,
      "body": "LY3561774 (Solbinsiran) is a GalNAc-conjugated mRNA silencing agent that specifically targets ANGPTL3 expression in the liver. The reduction of ANGPTL3 protein will reduce certain classes of circulating lipids. It is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).\n",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Solbinsiran",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3561774 (Solbinsiran) is a GalNAc-conjugated mRNA silencing agent that specifically targets ANGPTL3 expression in the liver. The reduction of ANGPTL3 protein will reduce certain classes of circulating lipids. It is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).</p>",
      "mainTitle": "Solbinsiran",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "CVD",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2928,
      "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of Morbidity and Mortality in Obesity.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": " Tirzepatide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of Morbidity and Mortality in Obesity.</p>",
      "mainTitle": " Tirzepatide",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Morbidity and Mortality in Obesity",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2929,
      "body": "LY3372993 (Remternetug) is a biologic entity that binds to deposited amyloid plaque in the brain and is being studied for the treatment of early Alzheimer's disease, with potential for subcutaneous delivery.\n",
      "news": [],
      "type": "nme",
      "phase": 3,
      "state": null,
      "title": "Remternetug",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3372993 (Remternetug) is a biologic entity that binds to deposited amyloid plaque in the brain and is being studied for the treatment of early Alzheimer's disease, with potential for subcutaneous delivery.</p>",
      "mainTitle": "Remternetug",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Alzheimer's Disease ",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2922,
      "body": "“[Ac-225]-PSMA-62” is a radioligand therapy being studied for the treatment of prostate cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "named",
      "title": "[Ac-225]-PSMA-62",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "“[Ac-225]-PSMA-62” is a radioligand therapy being studied for the treatment of prostate cancer.",
      "mainTitle": "[Ac-225]-PSMA-62",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Prostate Cancer ",
      "stateTitle": "NAMED",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:13:52.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2924,
      "body": "LY3473329 (Muvalaplin) is a chemical entity that disrupts lipoprotein(a) (Lp[a]) formation. LY3473329 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).\n",
      "news": [
        {
          "id": 2067,
          "url": "https://lilly.mediaroom.com/2024-11-18-Lillys-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-by-up-to-85-at-highest-tested-dose",
          "date": "2024-11-18T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2924,
          "formattedDate": "November 18, 2024",
          "formattedDateTime": "November 18, 2024"
        }
      ],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Muvalaplin",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3473329 (Muvalaplin) is a chemical entity that disrupts lipoprotein(a) (Lp[a]) formation. LY3473329 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).\n",
      "mainTitle": "Muvalaplin",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "ASCVD",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:38:27.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2930,
      "body": "\"Glucose sensing insulin receptor agonist\" is a biologic entity being studied for the treatment of diabetes.\n",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "GS Insulin Receptor Agonist",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>&quot;Glucose sensing insulin receptor agonist&quot; is a biologic entity being studied for the treatment of diabetes.</p>",
      "mainTitle": "GS Insulin Receptor Agonist",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Diabetes",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2935,
      "body": "\"Macupatide\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "Macupatide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"Macupatide\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "mainTitle": "Macupatide",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cardiometabolic Health",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2940,
      "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a first line treatment of CLL.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Pirtobrutinib   ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>&quot;Pirtobrutinib&quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a first line treatment of CLL.</p>",
      "mainTitle": "Pirtobrutinib   ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "1L CLL monotherapy ",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2946,
      "body": "LY3527723 \"Selpercatinib\" is a chemical entity that inhibits the rearranged during transfection (RET) kinase. It is being studied in the treatment of adjuvant RET fusion+ non small cell lung cancer after surgery / chemotherapy / radiotherapy.\n",
      "news": [
        {
          "id": 2085,
          "url": "https://lilly.mediaroom.com/2023-10-21-Lillys-Retevmo-R-selpercatinib-Phase-3-Results-in-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-and-RET-Mutant-Medullary-Thyroid-Cancer-Both-Published-in-The-New-England-Journal-of-Medicine-and-Presented-in-a-Presidential-Symposium-at-ESMO-Con",
          "date": "2023-10-21T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published ",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2946,
          "formattedDate": "October 21, 2023",
          "formattedDateTime": "October 21, 2023"
        },
        {
          "id": 2088,
          "url": "http://lilly.mediaroom.com/2022-04-01-Lilly-Presents-Updated-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-NSCLC-at-the-2022-European-Lung-Cancer-Congress",
          "date": "2022-04-01T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2946,
          "formattedDate": "April 01, 2022",
          "formattedDateTime": "April 01, 2022"
        }
      ],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Selpercatinib ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY3527723 &quot;Selpercatinib&quot; is a chemical entity that inhibits the rearranged during transfection (RET) kinase. It is being studied in the treatment of adjuvant RET fusion+ non small cell lung cancer after surgery / chemotherapy / radiotherapy.</p>",
      "mainTitle": "Selpercatinib ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Adjuvant RET+ NSCLC",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2950,
      "body": "LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of HR+ HER2- advanced or metastatic breast cancer in combination with fulvestrant following progression on a CDK4 & 6 inhibitor and endocrine therapy.\n",
      "news": [
        {
          "id": 2091,
          "url": "http://lilly.mediaroom.com/2023-03-03-U-S-FDA-Broadens-Indication-for-Verzenio-R-abemaciclib-in-HR-,-HER2-,-Node-Positive,-High-Risk-Early-Breast-Cancer",
          "date": "2023-03-03T00:00:00.000Z",
          "type": "Press Release",
          "title": "U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2950,
          "formattedDate": "March 03, 2023",
          "formattedDateTime": "March 03, 2023"
        },
        {
          "id": 2090,
          "url": "http://lilly.mediaroom.com/2022-12-06-Lilly-Announces-Updated-Data-from-the-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Presented-at-SABCS-and-Simultaneously-Published-in-The-Lancet-Oncology",
          "date": "2022-12-06T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2950,
          "formattedDate": "December 06, 2022",
          "formattedDateTime": "December 06, 2022"
        },
        {
          "id": 2089,
          "url": "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium",
          "date": "2022-11-21T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2950,
          "formattedDate": "November 21, 2022",
          "formattedDateTime": "November 21, 2022"
        }
      ],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Abemaciclib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of HR+ HER2- advanced or metastatic breast cancer in combination with fulvestrant following progression on a CDK4 &amp; 6 inhibitor and endocrine therapy.</p>",
      "mainTitle": "Abemaciclib",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "MBC Sequencing",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2959,
      "body": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Ulcerative Colitis.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": "n/a",
      "title": "MORF-057 ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Ulcerative Colitis.",
      "mainTitle": "MORF-057 ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Ulcerative Colitis",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2968,
      "body": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of chronic rhinosinusitis with nasal polyps.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "n/a",
      "title": "Lebrikizumab ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of chronic rhinosinusitis with nasal polyps.",
      "mainTitle": "Lebrikizumab ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "CRSwNP",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2985,
      "body": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (all PD-L1 expressors) in combination with pembrolizumab and platinum-based chemotherapy.",
      "news": [
        {
          "id": 2093,
          "url": "https://lilly.mediaroom.com/2024-06-01-Updated-Data-from-the-Phase-1-2-Study-of-Olomorasib-in-KRAS-G12C-Mutant-Advanced-Solid-Tumors-Presented-at-the-2024-ASCO-R-Annual-Meeting",
          "date": "2024-06-01T00:00:00.000Z",
          "type": "Press Release",
          "title": "Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2985,
          "formattedDate": "June 01, 2024",
          "formattedDateTime": "June 01, 2024"
        }
      ],
      "type": "nme",
      "phase": 3,
      "state": "n/a",
      "title": "Olomorasib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (all PD-L1 expressors) in combination with pembrolizumab and platinum-based chemotherapy.",
      "mainTitle": "Olomorasib",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "KRAS G12C-mutant NSCLC (All PD-L1)",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:42:43.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2975,
      "body": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (PD-L1 high expressors) in combination with pembrolizumab.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "n/a",
      "title": "Olomorasib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in 1L KRAS G12C-mutant NSCLC (PD-L1 high expressors) in combination with pembrolizumab.",
      "mainTitle": "Olomorasib",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "KRAS G12C-mutant NSCLC (PD-L1 high)",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:51:40.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2931,
      "body": "\"GBA1 Gene Therapy\" is a gene therapy being developed for patients with Gaucher Disease Type 1, which is an autosomal recessive inherited disease.\n",
      "news": [],
      "type": "indication",
      "phase": 2,
      "state": null,
      "title": "GBA1 Gene Therapy",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>&quot;GBA1 Gene Therapy&quot; is a gene therapy being developed for patients with Gaucher Disease Type 1, which is an autosomal recessive inherited disease.</p>",
      "mainTitle": "GBA1 Gene Therapy",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Gaucher Disease Type 1",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2943,
      "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied for the treatment of patients with R/R MCL who have received prior BTKi therapies.\n",
      "news": [
        {
          "id": 2077,
          "url": "https://lilly.mediaroom.com/2023-12-11-Updated-Data-from-the-BRUIN-Phase-1-2-Study-of-Pirtobrutinib-in-Chronic-Lymphocytic-Leukemia-and-Mantle-Cell-Lymphoma-Presented-at-the-2023-ASH-Annual-Meeting",
          "date": "2023-12-11T00:00:00.000Z",
          "type": "Press Release",
          "title": "Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2943,
          "formattedDate": "December 11, 2023",
          "formattedDateTime": "December 11, 2023"
        },
        {
          "id": 2069,
          "url": "https://lilly.mediaroom.com/2023-11-02-Lilly-Announces-Details-of-Pirtobrutinib-Presentations-in-B-Cell-Malignancies-at-2023-ASH-Annual-Meeting",
          "date": "2023-11-02T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2943,
          "formattedDate": "November 02, 2023",
          "formattedDateTime": "November 02, 2023"
        },
        {
          "id": 2070,
          "url": "http://lilly.mediaroom.com/2023-01-27-U-S-FDA-Approves-Jaypirca-TM-pirtobrutinib-,-the-First-and-Only-Non-Covalent-Reversible-BTK-Inhibitor,-for-Adult-Patients-with-Relapsed-or-Refractory-Mantle-Cell-Lymphoma-After-at-Least-Two-Lines-of-Systemic-Therapy,-Including-a-BTK-Inhibitor",
          "date": "2023-01-27T00:00:00.000Z",
          "type": "Press Release",
          "title": "U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2943,
          "formattedDate": "January 27, 2023",
          "formattedDateTime": "January 27, 2023"
        }
      ],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Pirtobrutinib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>&quot;Pirtobrutinib&quot; is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied for the treatment of patients with R/R MCL who have received prior BTKi therapies.</p>",
      "mainTitle": "Pirtobrutinib",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "R/R MCL monotherapy",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2947,
      "body": "PNPLA3 siRNA is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "PNPLA3 siRNA",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "PNPLA3 siRNA is a small interfering RNA (siRNA) being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
      "mainTitle": "PNPLA3 siRNA",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "MASH",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2954,
      "body": "LY3556050 (Mazisotine) is a small molecule SSTR4 agonist designed to modulate somatostatin signaling, impacting nerve excitability, resulting in improved regulation of inflammation and pain. It is being developed for treatment of pain.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Mazisotine",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3556050 (Mazisotine) is a small molecule SSTR4 agonist designed to modulate somatostatin signaling, impacting nerve excitability, resulting in improved regulation of inflammation and pain. It is being developed for treatment of pain.",
      "mainTitle": "Mazisotine",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Pain",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 304,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2965,
      "body": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.\n",
      "news": [
        {
          "id": 2098,
          "url": "http://lilly.mediaroom.com/2023-06-23-Lillys-phase-2-results-published-in-the-New-England-Journal-of-Medicine-show-orforglipron,-a-once-daily-oral-nonpeptide-GLP-1-receptor-agonist,-achieved-up-to-14-7-mean-weight-reduction-at-36-weeks-in-adults-with-obesity-or-overweight",
          "date": "2023-06-23T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweigh",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2965,
          "formattedDate": "June 23, 2023",
          "formattedDateTime": "June 23, 2023"
        }
      ],
      "type": "nme",
      "phase": 3,
      "state": null,
      "title": "Orforglipron ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.</p>",
      "mainTitle": "Orforglipron ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Obesity",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2977,
      "body": "LY3484356 “Imlunestrant\" is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).\n",
      "news": [
        {
          "id": 2101,
          "url": "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium",
          "date": "2022-11-21T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2977,
          "formattedDate": "November 21, 2022",
          "formattedDateTime": "November 21, 2022"
        }
      ],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Imlunestrant  ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY3484356 “Imlunestrant&quot; is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).</p>",
      "mainTitle": "Imlunestrant  ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Adjuvant Breast Cancer",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2993,
      "body": "\"FXR Agonist (FXR314)\" is a  biologic entity being studied for the treatment of autoimmune diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "new",
      "title": "FXR Agonist (FXR314)",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"FXR Agonist (FXR314)\" is a  biologic entity being studied for the treatment of autoimmune diseases.",
      "mainTitle": "FXR Agonist (FXR314)",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:28:03.000Z",
      "indication": "Immunology",
      "stateTitle": "NEW",
      "typeFilter": "nme",
      "updated_at": "2025-04-29T15:09:38.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2992,
      "body": "“Anti-VEGF Gene Therapy” is a gene therapy being studied for the treatment of vestibular schwannoma.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "new",
      "title": "Anti-VEGF Gene Therapy    ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "“Anti-VEGF Gene Therapy” is a gene therapy being studied for the treatment of vestibular schwannoma.",
      "mainTitle": "Anti-VEGF Gene Therapy    ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:23:58.000Z",
      "indication": "Vestibular Schwannoma",
      "stateTitle": "NEW",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T19:19:37.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2938,
      "body": "LY3484356 “Imlunestrant\" is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of 2nd line Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) metastatic Breast Cancer (mBC) as a monotherapy and in combination with abemaciclib.",
      "news": [
        {
          "id": 2075,
          "url": "https://lilly.mediaroom.com/2024-12-11-Lillys-Imlunestrant,-an-Oral-SERD,-Significantly-Improved-Progression-Free-Survival-as-Monotherapy-and-in-Combination-with-Verzenio-R-abemaciclib-in-Patients-with-ER-,-HER2-Advanced-Breast-Cancer",
          "date": "2024-12-11T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2938,
          "formattedDate": "December 11, 2024",
          "formattedDateTime": "December 11, 2024"
        },
        {
          "id": 2073,
          "url": "https://lilly.mediaroom.com/2024-11-01-Lilly-to-Present-Results-from-Phase-3-EMBER-3-Study-of-Imlunestrant,-an-Oral-SERD,-and-Additional-Results-from-Its-Breast-Cancer-Portfolio-at-the-San-Antonio-Breast-Cancer-Symposium",
          "date": "2024-11-01T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2938,
          "formattedDate": "November 01, 2024",
          "formattedDateTime": "November 01, 2024"
        },
        {
          "id": 2071,
          "url": "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium",
          "date": "2022-11-21T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2938,
          "formattedDate": "November 21, 2022",
          "formattedDateTime": "November 21, 2022"
        }
      ],
      "type": "nme",
      "phase": 4,
      "state": "n/a",
      "title": "Imlunestrant",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3484356 “Imlunestrant\" is a chemical entity that functions as an oral Selective Estrogen Receptor Degrader (SERD). It is being studied for the treatment of 2nd line Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) metastatic Breast Cancer (mBC) as a monotherapy and in combination with abemaciclib.",
      "mainTitle": "Imlunestrant",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "ER+ HER2- mBC",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T19:29:44.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2996,
      "body": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Rheumatoid Arthritis. ",
      "news": [],
      "type": "indication",
      "phase": 2,
      "state": "new",
      "title": "CD19 Antibody",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Rheumatoid Arthritis. ",
      "mainTitle": "CD19 Antibody",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:39:38.000Z",
      "indication": "Rheumatoid Arthritis",
      "stateTitle": "NEW",
      "typeFilter": "nilex",
      "updated_at": "2025-04-29T15:08:12.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2994,
      "body": "\"Integrin α5β1\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "new",
      "title": "Integrin α5β1",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"Integrin α5β1\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "mainTitle": "Integrin α5β1",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:29:42.000Z",
      "indication": "Cardiometabolic Health",
      "stateTitle": "NEW",
      "typeFilter": "nme",
      "updated_at": "2025-04-29T15:10:07.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2932,
      "body": "LY3841136 (Eloralintide) is a biologic entity that acts as a selective amylin receptor agonist. It is being studied for the treatment of obesity.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": "named",
      "title": "Eloralintide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3841136 (Eloralintide) is a biologic entity that acts as a selective amylin receptor agonist. It is being studied for the treatment of obesity.",
      "mainTitle": "Eloralintide",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Obesity ",
      "stateTitle": "NAMED",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2936,
      "body": "\"SNCA siRNA\" is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "SNCA siRNA",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"SNCA siRNA\" is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
      "mainTitle": "SNCA siRNA",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Neurodegeneration",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2941,
      "body": "LY3972406 (Kv1.3 Antagonist) is a highly selective small molecule inhibitor of the ion channel protein Kv1.3. LY3972406 is being studied for the treatment of psoriasis.\n",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Kv1.3 Antagonist",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY3972406 (Kv1.3 Antagonist) is a highly selective small molecule inhibitor of the ion channel protein Kv1.3. LY3972406 is being studied for the treatment of psoriasis.</p>",
      "mainTitle": "Kv1.3 Antagonist",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Psoriasis",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2944,
      "body": "\"GIP/GLP-1 Coagonist III\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "GIP/GLP-1 Coagonist III ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"GIP/GLP-1 Coagonist III\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "mainTitle": "GIP/GLP-1 Coagonist III ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cardiometabolic Health",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2949,
      "body": "LY3819469 (Lepodisiran) is a GalNAc-conjugated small interfering RNA (siRNA) that inhibits the production of apolipoprotein(a) (Apo[a]), thereby reducing levels of lipoprotein(a) (Lp[a]). LY3819469 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).",
      "news": [
        {
          "id": 2108,
          "url": "https://lilly.mediaroom.com/2025-03-30-Lillys-lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor,-lipoprotein-a-,-by-nearly-94-from-baseline-at-the-highest-tested-dose-in-adults-with-elevated-levels",
          "date": "2025-03-30T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels",
          "created_at": "2025-04-29T17:27:37.000Z",
          "updated_at": "2025-04-29T17:28:09.000Z",
          "molecule_id": 2949,
          "formattedDate": "March 30, 2025",
          "formattedDateTime": "March 30, 2025"
        }
      ],
      "type": "nme",
      "phase": 3,
      "state": "named",
      "title": "Lepodisiran",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3819469 (Lepodisiran) is a GalNAc-conjugated small interfering RNA (siRNA) that inhibits the production of apolipoprotein(a) (Apo[a]), thereby reducing levels of lipoprotein(a) (Lp[a]). LY3819469 is being studied for the treatment of atherosclerotic cardiovascular disease (ASCVD).",
      "mainTitle": "Lepodisiran",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "ASCVD",
      "stateTitle": "NAMED",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2963,
      "body": "\"GRN Gene Therapy\" is a gene therapy being developed for patients with frontotemporal dementia with GRN mutations (FTD-GRN).\n\n",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "GRN Gene Therapy  ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>&quot;GRN Gene Therapy&quot; is a gene therapy being developed for patients with frontotemporal dementia with GRN mutations (FTD-GRN).</p>",
      "mainTitle": "GRN Gene Therapy  ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Frontotemporal Dementia",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2974,
      "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied to assess initial safety, pharmacokinetic (PK) and efficacy of higher investigational doses in participants with Type 2 Diabetes and Obesity (BMI ≥35).\n",
      "news": [],
      "type": "indication",
      "phase": 2,
      "state": null,
      "title": " Tirzepatide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied to assess initial safety, pharmacokinetic (PK) and efficacy of higher investigational doses in participants with Type 2 Diabetes and Obesity (BMI ≥35).</p>",
      "mainTitle": " Tirzepatide",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Higher Doses",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2971,
      "body": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a monotherapy for the treatment of  R/R CLL in BTK pre-treated patients.",
      "news": [
        {
          "id": 2097,
          "url": "https://lilly.mediaroom.com/2024-12-09-Phase-3-results-for-Lillys-Jaypirca-R-pirtobrutinib-in-covalent-BTK-inhibitor-pre-treated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-to-be-presented-at-the-2024-ASH-Annual-Meeting",
          "date": "2024-12-09T00:00:00.000Z",
          "type": "Press Release",
          "title": "Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2971,
          "formattedDate": "December 09, 2024",
          "formattedDateTime": "December 09, 2024"
        },
        {
          "id": 2095,
          "url": "https://lilly.mediaroom.com/2024-11-05-Lilly-announces-details-of-presentations-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting",
          "date": "2024-11-05T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2971,
          "formattedDate": "November 05, 2024",
          "formattedDateTime": "November 05, 2024"
        },
        {
          "id": 2094,
          "url": "https://lilly.mediaroom.com/2023-12-11-Updated-Data-from-the-BRUIN-Phase-1-2-Study-of-Pirtobrutinib-in-Chronic-Lymphocytic-Leukemia-and-Mantle-Cell-Lymphoma-Presented-at-the-2023-ASH-Annual-Meeting",
          "date": "2023-12-11T00:00:00.000Z",
          "type": "Press Release",
          "title": "Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2971,
          "formattedDate": "December 11, 2023",
          "formattedDateTime": "December 11, 2023"
        },
        {
          "id": 2096,
          "url": "https://lilly.mediaroom.com/2023-11-02-Lilly-Announces-Details-of-Pirtobrutinib-Presentations-in-B-Cell-Malignancies-at-2023-ASH-Annual-Meeting",
          "date": "2023-11-02T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2971,
          "formattedDate": "November 02, 2023",
          "formattedDateTime": "November 02, 2023"
        }
      ],
      "type": "indication",
      "phase": 5,
      "state": "milestone",
      "title": "Pirtobrutinib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "\"Pirtobrutinib\" is a chemical entity that inhibits the Bruton's tyrosine kinase. Pirtobrutinib is being studied as a monotherapy for the treatment of  R/R CLL in BTK pre-treated patients.",
      "mainTitle": "Pirtobrutinib",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": " R/R CLL monotherapy",
      "stateTitle": "MILESTONE",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:53:36.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": true
    },
    {
      "id": 2958,
      "body": "LY4100511 (Simepdekinra) is a small-molecule inhibitor of the cytokine interleukin (IL)-17 and is being developed as an oral therapy for psoriasis.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": "n/a",
      "title": "Simepdekinra ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY4100511 (Simepdekinra) is a small-molecule inhibitor of the cytokine interleukin (IL)-17 and is being developed as an oral therapy for psoriasis.",
      "mainTitle": "Simepdekinra ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Psoriasis",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:37:25.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2997,
      "body": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with moderate-to-severe plaque psoriasis and obesity or overweight.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "n/a",
      "title": "Ixekizumab + Tirzepatide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with moderate-to-severe plaque psoriasis and obesity or overweight.",
      "mainTitle": "Ixekizumab + Tirzepatide",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:49:08.000Z",
      "indication": "Psoriasis",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-29T15:11:19.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2999,
      "body": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in Adjuvant KRAS G12C-mutant resected NSCLC in combination with pembrolizumab.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "new",
      "title": "Olomorasib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3537982 “Olomorasib” is a second-generation oral small molecule inhibitor of mutant KRAS G12C. It is being developed as a targeted therapy in Adjuvant KRAS G12C-mutant resected NSCLC in combination with pembrolizumab.",
      "mainTitle": "Olomorasib",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:52:04.000Z",
      "indication": "Adjuvant KRAS G12C-mutant resected NSCLC",
      "stateTitle": "NEW",
      "typeFilter": "nilex",
      "updated_at": "2025-04-29T15:47:17.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2995,
      "body": "\"PI3Kα Inhibitor (STX-478)\" is a chemical entity being studied for the treatment of cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "new",
      "title": "PI3Kα Inhibitor (STX-478)",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "\"PI3Kα Inhibitor (STX-478)\" is a chemical entity being studied for the treatment of cancer.",
      "mainTitle": "PI3Kα Inhibitor (STX-478)",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:34:59.000Z",
      "indication": "Cancer",
      "stateTitle": "NEW",
      "typeFilter": "nme",
      "updated_at": "2025-04-29T15:10:39.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2998,
      "body": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with active psoriatic arthritis and obesity or overweight.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "n/a",
      "title": "Ixekizumab + Tirzepatide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "A concomitant administration of LY2439821 \"Ixekizumab\" and LY3298176 \"Tirzepatide\" is being studied for the treatment of adults with active psoriatic arthritis and obesity or overweight.",
      "mainTitle": "Ixekizumab + Tirzepatide",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:50:23.000Z",
      "indication": " Psoriatic Arthritis",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-29T15:11:08.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2933,
      "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of adverse CV outcomes in patients with type 2 diabetes.\n",
      "news": [
        {
          "id": 2099,
          "url": "http://lilly.mediaroom.com/2021-05-20-Lillys-tirzepatide-achieves-all-primary-and-key-secondary-study-outcomes-against-insulin-glargine-in-adults-with-type-2-diabetes-and-increased-cardiovascular-risk-in-SURPASS-4-trial",
          "date": "2021-05-20T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2933,
          "formattedDate": "May 20, 2021",
          "formattedDateTime": "May 20, 2021"
        },
        {
          "id": 2100,
          "url": "http://lilly.mediaroom.com/index.php?s=9042&item=138059",
          "date": "2020-06-09T00:00:00.000Z",
          "type": "Press Release",
          "title": "First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2933,
          "formattedDate": "June 09, 2020",
          "formattedDateTime": "June 09, 2020"
        }
      ],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": " Tirzepatide  ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the reduction of adverse CV outcomes in patients with type 2 diabetes.</p>",
      "mainTitle": " Tirzepatide  ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "CV Outcomes",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2937,
      "body": "\"GIPR Agonist Long Acting\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "GIPR Agonist Long Acting  ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"GIPR Agonist Long Acting\" is a biologic entity being studied for the treatment of cardiometabolic-related diseases.",
      "mainTitle": "GIPR Agonist Long Acting  ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cardiometabolic Health",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2942,
      "body": "LY3209590 \"Insulin Efsitora Alfa\" is a biologic entity comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.\n",
      "news": [
        {
          "id": 2076,
          "url": "https://lilly.mediaroom.com/2024-09-10-Once-weekly-dose-of-insulin-efsitora-alfa-delivers-A1C-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes",
          "date": "2024-09-10T00:00:00.000Z",
          "type": "Press Release",
          "title": "Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2942,
          "formattedDate": "September 10, 2024",
          "formattedDateTime": "September 10, 2024"
        },
        {
          "id": 2072,
          "url": "https://lilly.mediaroom.com/2024-09-05-In-a-first-of-its-kind-fixed-dose-study,-once-weekly-insulin-efsitora-alfa-leads-to-A1C-reduction-similar-to-daily-insulin",
          "date": "2024-09-05T00:00:00.000Z",
          "type": "Press Release",
          "title": "In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2942,
          "formattedDate": "September 05, 2024",
          "formattedDateTime": "September 05, 2024"
        },
        {
          "id": 2074,
          "url": "https://lilly.mediaroom.com/2024-05-16-With-Once-a-Week-Dosing,-Insulin-Efsitora-Alfa-Delivers-A1C-Reduction-and-Safety-Profile-Consistent-with-Daily-Insulin",
          "date": "2024-05-16T00:00:00.000Z",
          "type": "Press Release",
          "title": "With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2942,
          "formattedDate": "May 16, 2024",
          "formattedDateTime": "May 16, 2024"
        }
      ],
      "type": "nme",
      "phase": 3,
      "state": null,
      "title": "Insulin Efsitora Alfa",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3209590 &quot;Insulin Efsitora Alfa&quot; is a biologic entity comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.</p>",
      "mainTitle": "Insulin Efsitora Alfa",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Diabetes",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2948,
      "body": "\"Nectin-4 ADC 1\" is a biologic entity being studied for the treatment of cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "named",
      "title": "Nectin-4 ADC 1",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"Nectin-4 ADC 1\" is a biologic entity being studied for the treatment of cancer.",
      "mainTitle": "Nectin-4 ADC 1",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cancer",
      "stateTitle": "NAMED",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2957,
      "body": "LY3848575 (Epiregulin mAb) is a monoclonal antibody that binds to human epiregulin, preventing epiregulin binding to and activation of its receptors. It is being studied for the treatment of chronic pain.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": "n/a",
      "title": "Epiregulin Antibody",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3848575 (Epiregulin mAb) is a monoclonal antibody that binds to human epiregulin, preventing epiregulin binding to and activation of its receptors. It is being studied for the treatment of chronic pain.",
      "mainTitle": "Epiregulin Antibody",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Pain",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 304,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2969,
      "body": "LY3154207 (Mevidalen) is a chemical entity that acts as a positive allosteric modulator of the dopamine receptor D1 and is being studied for the symptomatic treatment of Alzheimer's disease.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Mevidalen",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3154207 (Mevidalen) is a chemical entity that acts as a positive allosteric modulator of the dopamine receptor D1 and is being studied for the symptomatic treatment of Alzheimer's disease.",
      "mainTitle": "Mevidalen",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Symptomatic Alzheimer's disease  ",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2983,
      "body": "\"FRa ADC\" is a biologic entity being studied for the treatment of cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "FRa ADC ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"FRa ADC\" is a biologic entity being studied for the treatment of cancer.",
      "mainTitle": "FRa ADC ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cancer ",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2990,
      "body": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of Obstructive Sleep Apnea.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "n/a",
      "title": "Orforglipron",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of Obstructive Sleep Apnea.",
      "mainTitle": "Orforglipron",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Obstructive Sleep Apnea",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-29T15:05:59.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2934,
      "body": "LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of type 2 diabetes.\n",
      "news": [
        {
          "id": 2109,
          "url": "https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically",
          "date": "2025-04-17T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial",
          "created_at": "2025-04-29T17:29:34.000Z",
          "updated_at": "2025-04-29T17:30:03.000Z",
          "molecule_id": 2934,
          "formattedDate": "April 17, 2025",
          "formattedDateTime": "April 17, 2025"
        },
        {
          "id": 2104,
          "url": "http://lilly.mediaroom.com/2023-06-23-Lillys-phase-2-results-published-in-the-New-England-Journal-of-Medicine-show-orforglipron,-a-once-daily-oral-nonpeptide-GLP-1-receptor-agonist,-achieved-up-to-14-7-mean-weight-reduction-at-36-weeks-in-adults-with-obesity-or-overweight",
          "date": "2023-06-23T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweigh",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2934,
          "formattedDate": "June 23, 2023",
          "formattedDateTime": "June 23, 2023"
        }
      ],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Orforglipron ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of type 2 diabetes.</p>",
      "mainTitle": "Orforglipron ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Diabetes",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2939,
      "body": "LY3002813 (N3pG-Ab MAb) is a biologic entity that binds to deposited amyloid plaque in brain and is being studied for the treatment of preclinical Alzheimer's disease.\n",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": null,
      "title": "Donanemab",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3002813 (N3pG-Ab MAb) is a biologic entity that binds to deposited amyloid plaque in brain and is being studied for the treatment of preclinical Alzheimer's disease.</p>",
      "mainTitle": "Donanemab",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Preclinical Alzheimer's Disease ",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2945,
      "body": "LY3857210 (P2X7 Inhibitor) is an oral, highly selective, brain penetrant, small molecule antagonist of the ATP ligand-gated ion channel P2X7, which activates neuronal and non-neuronal cells in the peripheral and central nervous system pain pathways. It is being developed as treatment for chronic pain conditions.\n",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "P2X7 Inhibitor  ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY3857210 (P2X7 Inhibitor) is an oral, highly selective, brain penetrant, small molecule antagonist of the ATP ligand-gated ion channel P2X7, which activates neuronal and non-neuronal cells in the peripheral and central nervous system pain pathways. It is being developed as treatment for chronic pain conditions.</p>",
      "mainTitle": "P2X7 Inhibitor  ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Pain",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 304,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2951,
      "body": "\"Nectin-4 ADC 2\" is a biologic entity being studied for the treatment of cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "Nectin-4 ADC 2",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "\"Nectin-4 ADC 2\" is a biologic entity being studied for the treatment of cancer.",
      "mainTitle": "Nectin-4 ADC 2",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cancer",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2952,
      "body": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.  It is being studied for the treatment of T2DM.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "named",
      "title": "Retatrutide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.  It is being studied for the treatment of T2DM.",
      "mainTitle": "Retatrutide",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Diabetes",
      "stateTitle": "NAMED",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2953,
      "body": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Multiple Sclerosis.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": "named",
      "title": "CD19 Antibody",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3541860 “CD19 Antibody” is a novel, non-depleting antibody that inhibits B cell activity. It is being studied for the treatment of Multiple Sclerosis.",
      "mainTitle": "CD19 Antibody",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Multiple Sclerosis",
      "stateTitle": "NAMED",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2956,
      "body": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied for the treatment of Obesity, Osteoarthritis, and Obstructive Sleep Apnea with a planned simultaneous submission strategy.\n",
      "news": [
        {
          "id": 2102,
          "url": "http://lilly.mediaroom.com/2023-06-26-Lillys-phase-2-retatrutide-results-published-in-The-New-England-Journal-of-Medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-and-overweight",
          "date": "2023-06-26T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2956,
          "formattedDate": "June 26, 2023",
          "formattedDateTime": "June 26, 2023"
        }
      ],
      "type": "nme",
      "phase": 3,
      "state": null,
      "title": "Retatrutide ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied for the treatment of Obesity, Osteoarthritis, and Obstructive Sleep Apnea with a planned simultaneous submission strategy.</p>",
      "mainTitle": "Retatrutide ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Obesity, OA, OSA",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2955,
      "body": "\"Itaconate Mimetic\" is a chemical entity being studied for the treatment of autoimmune diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "Itaconate Mimetic",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>&quot;Itaconate Mimetic&quot; is a chemical entity being studied for the treatment of autoimmune diseases.</p>",
      "mainTitle": "Itaconate Mimetic",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Immunology ",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2960,
      "body": "LY3871801 (Ocadusertib) targets RIPK1, Receptor-interacting serine/threonine-protein kinase 1, a key mediator of cell death and inflammation. LY3871801 is being studied for the treatment of rheumatoid arthritis.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "Ocadusertib",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "<p>LY3871801 (Ocadusertib) targets RIPK1, Receptor-interacting serine/threonine-protein kinase 1, a key mediator of cell death and inflammation. LY3871801 is being studied for the treatment of rheumatoid arthritis.</p>",
      "mainTitle": "Ocadusertib",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Rheumatoid Arthritis",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2964,
      "body": "\"Long-Acting Atrial Natriuretic Peptide\" is a biologic entity being studied for the treatment of Heart Failure.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": null,
      "title": "LA-ANP",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>&quot;Long-Acting Atrial Natriuretic Peptide&quot; is a biologic entity being studied for the treatment of Heart Failure.</p>",
      "mainTitle": "LA-ANP",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Heart Failure",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2966,
      "body": "MAPT siRNA is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "MAPT siRNA",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "MAPT siRNA is a small interfering RNA (siRNA) being studied for the treatment of neurodegenerative diseases.",
      "mainTitle": "MAPT siRNA",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Neurodegeneration",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2967,
      "body": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied the reduction of adverse CV and renal outcomes in patients with obesity.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "n/a",
      "title": "Retatrutide ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3437943 (GIP/GLP-1/Glucagon Receptor Agonist) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being studied the reduction of adverse CV and renal outcomes in patients with obesity.",
      "mainTitle": "Retatrutide ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "CV / Renal Outcomes",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2970,
      "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",
      "news": [
        {
          "id": 2103,
          "url": "https://lilly.mediaroom.com/2024-06-08-Lillys-tirzepatide-was-superior-to-placebo-for-MASH-resolution,-and-more-than-half-of-patients-achieved-improvement-in-fibrosis-at-52-weeks",
          "date": "2024-06-08T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2970,
          "formattedDate": "June 08, 2024",
          "formattedDateTime": "June 08, 2024"
        }
      ],
      "type": "indication",
      "phase": 2,
      "state": null,
      "title": " Tirzepatide   ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).</p>",
      "mainTitle": " Tirzepatide   ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "MASH",
      "stateTitle": "",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2973,
      "body": "“OTOF Gene Therapy” is a gene therapy being developed for individuals with sensorineural hearing loss due to mutations in the Otoferlin gene. ",
      "news": [
        {
          "id": 2092,
          "url": "https://lilly.mediaroom.com/2024-01-23-Positive-Phase-1-2-Clinical-Trial-Data-for-an-Investigational-Gene-Therapy-for-Genetic-Hearing-Loss-to-be-Presented-at-the-Association-for-Research-in-Otolaryngology-2024-MidWinter-Meeting",
          "date": "2024-01-23T00:00:00.000Z",
          "type": "Press Release",
          "title": "Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2973,
          "formattedDate": "January 23, 2024",
          "formattedDateTime": "January 23, 2024"
        }
      ],
      "type": "nme",
      "phase": 2,
      "state": null,
      "title": "OTOF Gene Therapy",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "<p>“OTOF Gene Therapy” is a gene therapy being developed for individuals with sensorineural hearing loss due to mutations in the Otoferlin gene. </p>",
      "mainTitle": "OTOF Gene Therapy",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Hearing Loss",
      "stateTitle": "",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": null,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 302,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": null
    },
    {
      "id": 2972,
      "body": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of allergic rhinitis triggered by perennial allergens.",
      "news": [],
      "type": "indication",
      "phase": 3,
      "state": "n/a",
      "title": "Lebrikizumab",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3650150 “Lebrikizumab” is a monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. It is approved for the treatment of moderate to severe atopic dermatitis and it is being studied for the treatment of allergic rhinitis triggered by perennial allergens.",
      "mainTitle": "Lebrikizumab",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Allergic Rhinitis (perennial allergens)",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2991,
      "body": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of chronic heart failure with preserved ejection fraction.",
      "news": [
        {
          "id": 2086,
          "url": "https://lilly.mediaroom.com/2024-11-16-Lillys-tirzepatide-reduced-the-risk-of-worsening-heart-failure-events-by-38-in-adults-with-heart-failure-with-preserved-ejection-fraction-HFpEF-and-obesity",
          "date": "2024-11-16T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2991,
          "formattedDate": "November 16, 2024",
          "formattedDateTime": "November 16, 2024"
        },
        {
          "id": 2084,
          "url": "https://lilly.mediaroom.com/2024-08-01-Lillys-tirzepatide-successful-in-phase-3-study-showing-benefit-in-adults-with-heart-failure-with-preserved-ejection-fraction-and-obesity",
          "date": "2024-08-01T00:00:00.000Z",
          "type": "Press Release",
          "title": "Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity",
          "created_at": "2025-04-28T17:04:01.000Z",
          "updated_at": "2025-04-28T17:04:01.000Z",
          "molecule_id": 2991,
          "formattedDate": "August 01, 2024",
          "formattedDateTime": "August 01, 2024"
        }
      ],
      "type": "indication",
      "phase": 4,
      "state": "n/a",
      "title": "Tirzepatide",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3298176 (GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of chronic heart failure with preserved ejection fraction.",
      "mainTitle": "Tirzepatide",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "HFpEF",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T19:30:04.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2976,
      "body": "\"SMARCA2 (BRM)\" is a chemical entity being studied for the treatment of cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "SMARCA2 (BRM)",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "\"SMARCA2 (BRM)\" is a chemical entity being studied for the treatment of cancer.",
      "mainTitle": "SMARCA2 (BRM)",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cancer",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2984,
      "body": "LY3549492 (GLP-1 Receptor Non-peptide Agonist II) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.",
      "news": [],
      "type": "nme",
      "phase": 2,
      "state": "n/a",
      "title": "GLP-1R NPA II ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "LY3549492 (GLP-1 Receptor Non-peptide Agonist II) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity.",
      "mainTitle": "GLP-1R NPA II ",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Obesity ",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-29T15:07:19.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 303,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2978,
      "body": "\"KRAS G12D\" is a chemical entity being studied for the treatment of cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "KRAS G12D",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "\"KRAS G12D\" is a chemical entity being studied for the treatment of cancer.",
      "mainTitle": "KRAS G12D",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cancer ",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2988,
      "body": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Crohn’s Disease.",
      "news": [],
      "type": "indication",
      "phase": 2,
      "state": "n/a",
      "title": "MORF-057 ",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin being studied for the treatment of Crohn’s Disease.",
      "mainTitle": "MORF-057 ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Crohn’s Disease",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-28T17:04:00.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2989,
      "body": "LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Ulcerative Colitis alone and in combination with mirikizumab.",
      "news": [],
      "type": "indication",
      "phase": 2,
      "state": "n/a",
      "title": "Eltrekibart ",
      "page_id": 113,
      "modality": "biologic",
      "body_html": "LY3041658 (Eltrekibart) neutralizes chemokines that bind to the CXCR1 or CXCR2 receptors. LY3041658 is being studied for the treatment of Ulcerative Colitis alone and in combination with mirikizumab.",
      "mainTitle": "Eltrekibart ",
      "typeTitle": "New Indication",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Ulcerative Colitis ",
      "stateTitle": "N/A",
      "typeFilter": "nilex",
      "updated_at": "2025-04-29T15:06:35.000Z",
      "collaboration": false,
      "modalityTitle": "Large Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 301,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    },
    {
      "id": 2982,
      "body": "\"Pan KRAS\" is a chemical entity being studied for the treatment of cancer.",
      "news": [],
      "type": "nme",
      "phase": 1,
      "state": "n/a",
      "title": "Pan KRAS",
      "page_id": 113,
      "modality": "chemical",
      "body_html": "\"Pan KRAS\" is a chemical entity being studied for the treatment of cancer.",
      "mainTitle": "Pan KRAS",
      "typeTitle": "NME",
      "created_at": "2025-04-28T17:04:00.000Z",
      "indication": "Cancer ",
      "stateTitle": "N/A",
      "typeFilter": "nme",
      "updated_at": "2025-04-29T15:08:54.000Z",
      "collaboration": false,
      "modalityTitle": "Small Molecule",
      "pronunciation": null,
      "featured_links": [],
      "clinical_studies": [],
      "therapeutic_area_id": 300,
      "page_reference_title": "Q1 2025 Updates - Medicines in Development ",
      "regulatory_approval_achieved": false
    }
  ],
  "created_at": "2025-04-28T17:04:00.000Z",
  "intro_html": "Interested in Lilly clinical trials? Learn more at [LillyTrials.com](https://www.lillytrialguide.com/en-US?utm_source=ldc&utm_medium=organic&utm_campaign=ltg&utm_content=cdp)",
  "start_date": "February 6, 2025",
  "updated_at": "2025-04-29T17:22:18.000Z",
  "phase_titles": [
    "",
    "Phase 1",
    "Phase 2",
    "Phase 3",
    "Regulatory Review",
    "Regulatory Approval Achieved"
  ],
  "published_at": null,
  "approval_record": "CAR #5408",
  "reference_title": "Q1 2025 Updates - Medicines in Development ",
  "therapeutic_areas": [
    {
      "id": 300,
      "title": "Cancer",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 1,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    {
      "id": 301,
      "title": "Immunology",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 3,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    {
      "id": 302,
      "title": "Neurodegeneration",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 4,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    {
      "id": 303,
      "title": "Cardiometabolic Health",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 2,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    {
      "id": 304,
      "title": "Pain",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 5,
      "updated_at": "2025-04-28T17:04:00.000Z"
    }
  ],
  "approval_description": "Pre-launch state, inclusive of Q4 updates\nTanner Alexander shared staging site with team on Thursday, January 30. Lilly (Charles Clayton Persinger and G Stuart Gregory) approved changes to staging site on Tuesday, February 4. \n\n",
  "include_phase_numbers": false,
  "therapeutic_area_by_id": {
    "300": {
      "id": 300,
      "title": "Cancer",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 1,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    "301": {
      "id": 301,
      "title": "Immunology",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 3,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    "302": {
      "id": 302,
      "title": "Neurodegeneration",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 4,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    "303": {
      "id": 303,
      "title": "Cardiometabolic Health",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 2,
      "updated_at": "2025-04-28T17:04:00.000Z"
    },
    "304": {
      "id": 304,
      "title": "Pain",
      "page_id": 113,
      "created_at": "2025-04-28T17:04:00.000Z",
      "slug_index": 5,
      "updated_at": "2025-04-28T17:04:00.000Z"
    }
  }
}
